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ABSTRACT 
 
The sequencing of the human genome was expected to generate a veritable explosion 
of therapeutics for regulation of gene function, either through modulation of gene 
expression or through the replacement of defect genes. However, nucleic acid-based 
pharmacological agents suffer from issues of low bioavailability and unfavorable 
pharmacokinetics, wherefore these prospects have not yet been realized. 
One promising approach for regulation of gene function is a special type of 
antisense technology, referred to as splice correction. Aberrantly spliced mRNA is 
intimately associated with numerous serious illnesses, wherefore the ability to restore 
the correct splicing pattern is a highly attractive therapeutic approach. Another 
thriving oligonucleotide-based platform makes use of small (or short) interfering 
RNA (siRNA), double-stranded RNA sequences that efficiently silence expression of 
essentially any gene of interest. However, both platforms are limited by the inherent 
weaknesses of oligo- and polynucleotide-based agents, meaning that the development 
of efficient delivery vectors is a prerequisite for clinical translation. Short cationic 
peptide sequences, so called cell-penetrating peptides (CPPs), constitute an emerging 
category of delivery vehicles with the ability to convey various cargo molecules 
across the cell membrane, but numerous polymeric vectors (commonly referred to as 
„polyplexes‟) are also under intense scrutiny for delivery of gene-regulating agents.  
This thesis aims to delineate the internalization mechanisms of CPPs conjugated to 
a special type of splice-correcting oligonucleotide analogues (namely peptide nucleic 
acids (PNAs)), but it also presents a rationally modified CPP for delivery of splice-
correcting oligonucleotides and plasmid DNA, as well as an entirely novel class of 
delivery vectors, so called polythiophenes, for siRNA delivery. Specifically, paper I 
examines the internalization routes of a number of CPP-PNA conjugates, papers II 
and III study the oligonucleotide and plasmid delivery efficacy, respectively, of the 
stearylated CPP transportan 10 (TP10), whereas paper IV examines the utility of a 
cationic polythiophene for siRNA delivery.  
In conclusion, the research described herein provides novel data on internalization 
mechanisms of chemically distinct CPPs, as well as presents two novel agents for 
delivery of splice-correcting oligonucleotides, plasmid DNA, and siRNA, thereby 
adding additional tools to the toolbox for delivery of gene-regulating agents. 
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PREFACE 
 
The main framework and the overall contents of this doctoral thesis draw heavily on 
research carried out at the Department of Neurochemistry, Stockholm University, 
summarized and published in the licentiate thesis Cell-penetrating peptides in delivery 
of splice-correcting oligonucleotides (Lundin, P., Stockholm University, 
Universitetsservice, Stockholm, 2008, ISBN 978-91-7155-774-2).  
Specifically, paper I and paper II were present as manuscripts in the preceding thesis 
and the corresponding sections of the aims of the study, the methodological 
considerations, and the results and conclusions thus derive from this earlier publication. 
Furthermore, a substantial proportion of the introduction, in particular certain sections 
on cellular internalization mechanisms, antisense technology, alternative splicing, 
chemically modified nucleotides, and cell-penetrating peptides, originate from the 
licentiate thesis, although they have been revised and updated considerably to reflect 
the scientific progress over recent years.    
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1 INTRODUCTION 
 
1.1 A CRUCIAL BARRIER 
 
The human body is composed of trillions of cells, all with a specified function and 
with a distinct surrounding barrier. This barrier, the cell membrane, plays a number of 
fundamental roles for the cells‟ physiological functions; it is primarily a demarcating 
perimeter, separating the cell interior from the extracellular milieu and providing 
structural integrity, but it is also a point of contact, a scaffold for various types of 
macromolecules, and an entry barrier for most hydrophilic molecules. The membrane 
is primarily composed of phospholipids containing two separate domains, a polar 
head group and a hydrophobic fatty acid tail. As a result of the entropically driven 
hydrophobic effect these lipids form a virtually impermeable bilayer with a 
hydrophobic interior and a hydrophilic exterior. 
The relatively recent advances within biotechnology, together with the sequencing 
of the human genome (Venter et al., 2001; IHGSC, 2001), was expected to generate a 
veritable explosion of new genetic therapies to combat serious illnesses, either 
through classical replacement of defect genes or through oligonucleotide-based 
modulation of gene expression. However, as a result of the poor pharmacokinetic 
profiles and the low bioavailability of nucleic acid-based compounds, primarily as an 
implication of the presence of the plasma (cell) membrane, only a very limited 
number of therapies have actually reached the bedsides. In order to enable transport 
of nucleic acid-based pharmacological agents into the cell interior, both non-viral (i.e. 
chemical and mechanical) and viral vectors have over the years been evaluated as 
delivery vehicles for gene-regulating oligonucleotides and for entire genes (in the 
form of plasmid DNA). Alas, these carriers generally suffer either from low efficacy 
or from issues of questionable patient safety (Somia & Verma, 2000).  
Non-viral vectors normally share certain common denominators, such as positive 
charge and/or hydrophobicity, but the growing interest in drug delivery has generated 
a highly diverse flora of carrier compounds. One promising category of such non-
viral delivery agents that has received increasing attention since their initial discovery 
in 1994 (Derossi et al., 1994) is the cell-penetrating peptides (CPPs). Despite their 
physical characteristics and the impermeability of the cell membrane to large, charged 
compounds, this group of highly hydrophilic molecules has the surprising ability not 
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only to translocate across the lipid bilayer but also to carry various cargo molecules 
inside the cell. Although the CPP field has been expanding significantly over recent 
years, the major delivery workhorses within nucleic acid contexts are cationic lipids 
(lipoplexes) and cationic polymers (polyplexes). The cationic polymer most 
commonly employed for gene therapy purposes is probably poly(ethylenimine) (PEI), 
a linear or branched amine-containing hydrocarbon chain, but numerous other 
polymers of different origins are constantly being developed. 
The research presented in this thesis aims to devise strategies for traversing the 
entry barrier made up by the cell membrane, and the thesis spans the fields of cationic 
polymer- and CPP-mediated delivery of gene-regulating oligonucleotides and plasmid 
DNA, with specific foci on (i) the internalization mechanisms of a number of 
different CPPs conjugated to synthetic splice-correcting oligonucleotide analogues, as 
a means of delineating the endocytic internalization pathways of these short peptide 
vectors, (ii) development of a rationally designed chemically modified CPP with 
enhanced delivery properties, and (iii) the design of a novel cationic polymer vector 
for delivery of small interfering RNAs (siRNAs). 
 
1.1.1 Cellular transport mechanisms 
 
Despite its impermeability for large hydrophilic molecules, the plasma membrane 
does allow for vital small molecule-trafficking from the extracellular environment to 
the cytoplasm and other intracellular compartments. This type of membrane passage 
is based on either passive or active transport, mediated by specific membrane 
proteins, and it is limited to certain essential molecules.  
For macromolecule and particle trafficking, cells utilize a different, multifaceted 
transport mechanism known as endocytosis. Specialized cells, primarily the 
leukocytes of the immune system, are capable of a specific type of large-particle 
endocytic process known as phagocytosis, whereas all body cells utilize the highly 
diverse process of pinocytosis for fluid-phase ingestion. The endocytosis research 
field is constantly evolving, making pathway classifications somewhat momentary 
and often tailored for specific scientific purposes. One relatively recent general 
categorization is based on the involvement of the vesicle-coating protein clathrin 
(Mayor & Pagano, 2007), giving two broad classes, namely clathrin-mediated (CME) 
and clathrin-independent (CIE) endocytosis (Figure 1). There are however separate 
pathways of immense cellular importance slightly peripheral to the normal endocytic 
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mechanisms, with perhaps the most prominent one being the bulk uptake process of 
macropinocytosis (Swanson, 2008). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Recent endocytosis classification based on clathrin involvement, adapted from Mayor and 
Pagano (Mayor & Pagano, 2007). 
 
1.1.2 Clathrin-mediated endocytosis 
 
Clathrin, the coat protein behind the mechanistic endocytosis classification proposed 
by Mayor and Pagano, was first identified and isolated in the mid 1970s by the 
British cell biologist Barbara Pearse (Pearse, 1976). Adaptor protein recruitment of 
clathrin is the critical mechanism behind CME, a high-capacity process that occurs 
constitutively or in response to certain stimuli in all cell types as a pathway for 
internalization of, for instance, extracellular hormones and signalling factors (Takei & 
Haucke, 2001; Conner & Schmid, 2005; Howes et al., 2010). CME is intimately 
involved in various processes of crucial cellular importance, for instance neuronal 
synaptic vesicle retrieval (Girard et al., 2005), exo-endocytic receptor trafficking 
(Sheng & Kim, 2002), and neurotrophin uptake and sculpting of synaptic structure 
(Dickman, 2006). 
CME is initiated by ligand-receptor interactions resulting in a concentration of 
activated receptors binding to cytosolic adaptor proteins, forming a link to a clathrin 
lattice. The clustering of receptors generates clathrin-coated, shallow membrane pits 
that subsequently invaginate, elongate and pinch off (Conner & Schmid, 2005; 
Collins et al., 2011). As can be deduced from Figure 1, CME is by default dependent 
on the 100 kDa GTPase dynamin (Mayor & Pagano, 2007). Dynamin is believed to 
mediate the excision of the 100-110 nm clathrin-coated vesicle from the plasma 
membrane (Takei et al., 1995; Swanson, 2008; Howes et al., 2010), generating a 
Endocytic cargo 
Clathrin-mediated Clathrin-independent 
Dynamin-dependent Dynamin-independent Dynamin-dependent 
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vesicle for further cellular processing. It is worth noting that many accessory proteins 
play crucial roles in various functional aspects of CME: clathrin-associated sorting 
proteins (CLASPs) are involved in cargo selection; amphiphysins, endophilins, and 
epsins regulate coat maturation and invagination; and auxilin and synaptojanin are 
involved in vesicle uncoating (Jung & Haucke, 2007). 
 
1.1.3 Clathrin-independent endocytosis 
 
The clathrin-independent endocytic (CIE) pathways are not as extensively 
characterized as CME, but they are nevertheless broadly divided into a dynamin-
independent and a dynamin-dependent pathway, each consisting of multiple processes 
(Mayor & Pagano, 2007).  
One relatively well-characterized, dynamin-dependent CI pathway is caveolae- or 
raft-mediated endocytosis. This cholesterol-dependent pathway generates 50-80 nm 
flask-shaped invaginations enriched in cholesterol, sphingolipids, signalling proteins, 
and the cholesterol-binding hairpin-like integral membrane protein caveolin (Parton 
& Simmons, 2007). Endocytic cargoes include growth hormone receptors, cholera 
toxin subunit B, and viruses like SV40 (Parton & Richard, 2003). Another dynamin-
dependent pathway is mediated by the GTPase RhoA and this mechanism, which 
leads to formation of 50-60 nm vesicles, is responsible for certain immune cell and 
fibroblast protein internalizations, for instance the uptake of the β-chain of the 
interleukin-2 receptor (Mayor & Pagano, 2007; Howes et al., 2010). 
Many clathrin- and dynamin-independent pathways appear to have a common 
denominator in the involvement of small GTPases in the internalization mechanisms 
(Mayor & Pagano, 2007). The invaginations generated by these mechanisms often 
display rather distinctive morphological features, with long and wide surfaces 
surrounding a large volume of fluid (Sabharanjak et al., 2002). 
 
1.1.4 Macropinocytosis 
 
As the name implies, macropinocytosis belongs to the pinocytic internalization 
mechanisms but the pathway generates larger endocytic vesicles than commonly 
found within CME or CIE. In fact, macropinocytosis share a common feature with the 
large-scale uptake mechanism phagocytosis in that the Rho-family of GTPases 
triggers formation of actin-driven membrane protrusions (Conner & Schmid, 2005). 
   5 
Macropinosome formation is either spontaneous (non-specific) or a response to 
growth factor-receptor stimulation from cell surface ruffles that close down and 
engulf extracellular fluids, forming vesicles varying in size from 0.2 to 10 µm 
(Swanson, 2008), but perhaps more commonly from 1 to 5 µm (Hillaireau & 
Couvreur, 2009). 
The actin cytoskeleton movements are induced by the interactive effects of small 
(Ras-superfamily) GTPases and guanine exchange factors (GEFs) and results in flat 
sheet-like plasma membrane protrusions known as lamellipodia (Swanson, 2008). 
These structures either retract into the cytoplasm or close to form macropinosomes, a 
process that is, in certain cell types, induced by phosphatidyl-inositol 3-kinase (PI3K) 
(Araki et al., 1996). One interesting aspect of the macropinocytic internalization 
process, which perhaps can be exploited in drug delivery, are the results pointing 
toward macropinosomes bypassing the lysosomal pathway, as suggested by Hewlett 
and colleagues (Hewlett et al., 1994). Similarly, caveolae/raft-mediated endocytic 
processes appear not to generate acidified vesicles, but the resultant caveosomes have 
in fact been shown to display a neutral pH (Pelkmans & Helenius, 2002), meaning 
that the internalized delivery complex may fare better in caveosomes than in vesicular 
trafficking compartments resulting from other types of CIE or CME pathways. 
Although the exact intricacies of the various endocytosis pathways are still being 
investigated, it is clear that delivery vectors undergoing efficient endocytic 
internalization followed by endosomal escape could constitute an interesting platform 
for exploiting these endogenous uptake processes for drug delivery of compounds 
with low bioavailability, for instance nucleic acid-based material and proteins. 
 
1.2 GENE REGULATION: OLIGONUCLEOTIDE-MEDIATED 
MODULATION AND GENE THERAPY 
 
DNA, the genetic blueprint of all known living organisms, was first isolated almost 
one and a half decades ago, when the Swiss physician Friedrich Miescher was 
examining discarded surgical bandages (Miescher, 1871). The hereditary role of DNA 
was confirmed in the early 1950s, when Hershey and Chase showed that DNA was 
the genetic material of the T2 phage (Hershey & Chase, 1952), and the paramount 
breakthrough came just a few years later. Based on the X-ray diffraction images 
obtained by Rosalind Franklin (Franklin & Gosling, 1953), Watson and Crick 
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developed the first accurate model of the chemical structure of DNA (Watson & 
Crick, 1953), a discovery awarded with the Nobel Prize in Physiology or Medicine. 
Half a century later, with the sequencing of the human genome and the 
concomitant mapping of numerous disease-causing genes (Venter et al., 2001; 
IHGSC, 2001), the scene was set for rapid development of therapeutic agents for gene 
expression modulation. Together with the development of various tools for genetic 
interference, for instance the early demonstration in 1961 of hybridization-induced 
translation inhibition (Nireberg & Matthaei, 1961), the antisense proof-of-concept on 
Rous sarcoma virus (Stephenson & Zamecnik, 1978; Zamecnik & Stephenson, 1978), 
and the recent discovery of RNA interference (Fire et al., 1998), the knowledge of the 
alphabet of the human genome was supposed to aid in combating numerous serious 
illnesses. However, transitioning basic research to the bedsides has proven to be 
difficult, and although the toolbox for gene regulation surely is a powerful one it 
remains to be seen when, and if, the promises of modulation of gene function will 
translate into clinical impact.  
 
1.2.1 Antisense technology 
 
Pharmacological agents based on different antisense platforms have been undergoing 
considerable preclinical and clinical investigation for various ailments, including 
Duchenne muscular dystrophy (Yin et al., 2008; Goemans et al., 2011), inflammatory 
diseases such as Crohn‟s disease (Yacyshyn et al., 1998) and rheumatoid arthritis 
(Maksymowych et al., 2002), oncology indications such as non-Hodgkin‟s lymphoma 
(Waters et al., 2002), chronic lymphocytic leukemia (Dürig et al., 2011), and various 
solid malignancies (Crooke, 2001), as well as viral infections (Cheng et al., 1991). 
Antisense technology exploits the highly specific Watson-Crick hybridization of 
rather short oligonucleotides (approximately 15-25 nucleotides in length) to target 
RNA sequences in order to induce either enzymatic cleavage or steric obstruction of 
the ribosome, leading to translational arrest (Scherer & Rossi, 2003). There is a 
significant difference between these two approaches; when utilizing the antisense 
mechanism based on enzymatic cleavage, mediated by RNase H, the oligonucleotide 
concentration can be kept to a minimum as an implication of the multiple usage of the 
antisense agent, whereas the translational arrest strategy requires a vastly different 
stoichiometric relationship between the mRNA target and the therapeutic agent. 
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Despite the fact that the antisense paradigm was established already in the late 
1970s only one single antisense-based drug (called Fomivirsen) currently has 
regulatory approval. Fomivirsen (marketed as Vitravene
TM
) is a 21-mer 
phosphorothioate DNA oligonucleotide targeting viral mRNA corresponding to the 
coding region of the major immediate-early gene of human cytomegalovirus (CMV), 
and thereby inducing RNase H-mediated cleavage. Vitravene
TM
 is indicated for 
CMV-induced retinitis in immunocompromised patients and the drug is administered 
via intravitreal injection directly into the eye (Orr, 2001), thus bypassing the need for 
delivery vehicles, one of the aspects that has hampered drug development within the 
antisense field to date. 
One special type of antisense platform that appears to be reaching the bedsides 
within a relatively near future, at least for certain severe neuromuscular indications 
(Goemans et al., 2011), makes use of so called splice-correcting oligonucleotides. 
The ability to correct splicing has relatively recently emerged as an interesting 
therapeutic approach, concomitantly with the realization that aberrant splicing is 
intimately associated with several diseases, such as cystic fibrosis and β-thalassaemia 
(Faustino & Cooper, 2003), as well as with several types of neoplasia (Pajares et al., 
2007), and not least the debilitating disorders Duchenne muscular dystrophy (DMD) 
(Goemans et al., 2011) and spinal muscular dystrophy (Passini et al., 2011). 
 
1.2.2 Alternative splicing and splice correction 
 
As abovementioned, a specific type of antisense technology, based on splice-
correcting oligonucleotides, is attracting increasing attention as evidence accumulates 
on the involvement of alternative splicing in various pathological processes. Aberrant 
splicing is not only involved in the abovementioned well-known ailments but several 
other disorders, such as Menke‟s disease (Madsen et al., 2008), ataxia-telangiectasia 
(Du et al., 2007), X-linked agammaglobulinemia (Ochs & Smith, 1996), and 
Hutchinson-Gilford Progeria Syndrom (Scaffidi & Misteli, 2005), originate in 
dysfunctional splicing processes.  
The basis for the existence of alternative splicing is the presence of introns and 
exons in eukaryotic genes. Introns need to be removed prior to translation and this 
process is carried out by a sophisticated nuclear complex referred to as the 
spliceosome, comprising five types of small nuclear ribonucleoproteins (snRNPs) and 
hundreds of accessory proteins (Srebrow & Kornblihtt, 2006). On average, seven 
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splicing events occur per human pre-mRNA molecule, indicating the importance and 
critical nature of this process (Lander et al., 2001). The splicing mechanism is 
initiated when the spliceosome recognizes a 5‟ donor site beginning with a GU 
dinucleotide and a 3‟ acceptor site ending with an AG dinucleotide (in accordance 
with the co called “GU-AG rule”) (Srebrow & Kornblihtt, 2006). Generally, the 5‟ 
site is identified by U1 snRNP and the 3‟ site by U2 snRNP, whereas the auxiliary 
spliceosome factor U2AF associates with a polypyrimidine tract on the pre-mRNA 
and facilitates correct U2 binding (Sharp, 1994; Douglas & Wood, 2011). With the 
recruitment of three additional snRNPs the excision of the intron is accomplished. 
The main cause of alternative splicing is deviation from the consensus splice site 
sequence, generating a weak but functional site with lower affinity for the 
spliceosomal proteins and snRNPs (Srebrow & Kornblihtt, 2006). These sites are also 
influenced by so called enhancers and silencers, short stretches of approximately 10 
nucleotides exerting either positive or negative effects on the splice sites through the 
binding of regulatory proteins (Graveley, 2000) or through silencer-mediated 
formation of pre-mRNA secondary structures (Buratti et al., 2004). 
Approximately 15% of the mutations responsible for genetic disorders affect pre-
mRNA splicing, either through disruption or generation of splice sites (Srebrow & 
Kornblihtt, 2006). The ability to correct aberrant splicing was first realized in 1993, 
when a splice-correcting oligonucleotide was designed to block an activated cryptic 
splice site in thalassemic β-globin pre-mRNA, thereby obstructing the binding of the 
spliceosome and restoring normal splicing (Dominski & Kole, 1993). Since then, 
splice correction has made great strides toward the bedsides and ongoing clinical 
activities hold great promise for the treatment of, for instance, Duchenne muscular 
dystrophy (Kinali et al., 2009; Goemans et al., 2011). 
 
1.2.3 RNA interference 
 
Although discovered only slightly more than a decade ago (Fire et al., 1998), RNA 
interference (RNAi), a mechanism for controlling gene expression found in many 
eukaryotic organisms, has turned into a veritable laboratory workhorse within 
numerous fields, and its pioneers were awarded the 2006 Nobel Prize in Physiology 
or Medicine for their work. Like the antisense strategies, RNAi relies on the 
complementarity between an interfering RNA and its target mRNA, resulting in a 
powerful specificity and a for many purposes pivotal target discrimination.  
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The RNAi-mediated gene silencing pathway is initiated by the interaction between 
long stretches of dsRNA and the RNase III-like endoribonuclease Dicer, an enzyme 
that digests the strands into short (20-30 nucleotides) double stranded 
oligonucleotides with 2-nucleotide 3‟ overhangs (Bernstein et al., 2001; Czech & 
Hannon, 2011). Subsequently, these short endogenous, foreign (e.g. viral), or 
synthetically introduced oligonucleotides enter a multiprotein structure referred to as 
the RNA-induced silencing complex (RISC) (Hammond et al., 2000). A heterodimer 
of two proteins, termed R2D2 and Dicer-2, unwinds the dsRNA and directs 
incorporation of a single strand (the “guide” strand (Sano et al., 2008)) into the 
mature RISC. The assembly of the cleavage-competent, mature RISC is achieved by 
the exchange of Dicer for an RNA-cleaving Ago-2 enzyme, together with 
incorporation of various accessory proteins followed by scanning of the mRNA pool 
for complementary sites and subsequent mRNA cleavage (van den Berg et al., 2008; 
Czech & Hannon, 2011).  
The complementary of the RNA agent for the mRNA does not only convey 
unrivalled target specificity but it also mediates two distinct mechanisms depending 
on the degree of complementarity between the mRNA target and the seed region (i. e. 
the region responsible for target binding (Schwarz et al., 2006)) of the interfering 
RNA. Perfectly matching guide strands induce mRNA cleavage (in a 21-mer 
siRNA/mRNA duplex between positions 10 and 11 of the mRNA when counting 
from the 5‟ end of the antisense strand (Elbashir et al., 2001a)), whereas sequences 
with centrally bulging or imperfectly matching regions only promote translational 
inhibition (van den Berg et al., 2008). 
As indicated above, the endogenous process of RNA interference can be exploited 
using synthetic double-stranded RNAs and there are several approaches for efficient 
silencing of gene expression. The most commonly utilized RNAs for the induction of 
RNAi are synthetic short interfering RNAs (siRNAs) (Elbashir et al., 2001b), 
commonly delivered by chemical means, and short hairpin RNAs (shRNAs) 
transcribed from a DNA construct (Rayburn & Zhang, 2008). The relatively short 
(20-22 nucleotides) siRNAs and shRNAs were developed to circumvent the mounting 
of an anti-viral interferon response upon introduction of longer stretches of double-
stranded RNA (Rayburn & Zhang, 2008), but longer RNA stretches acting as Dicer 
substrates have been shown to enhance RNAi potency and efficacy (Kim et al., 
2005).  
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MicroRNAs (miRNAs), an abundant class of endogenous transcripts involved in 
the RNAi machinery, are naturally occurring mammalian post-transcriptional gene 
regulatory elements (Ambros, 2001; Pratt & MacRae, 2009), suggested to account for 
a large number of diseases, including numerous malignancies (Georges et al., 2007; 
Jeyaseelan et al., 2007). These evolutionary conserved sequences, derived from non-
coding regions, have been found in numerous species and their ability to reduce the 
level of their target transcripts is long-established, together with an involvement in 
such diverse and complex processes as cell proliferation control and brain patterning 
(Calin & Croce, 2006). miRNAs are generated from microprocessor complex-
mediated cleavage of precursor transcripts, generating a short-hairpin pre-miRNA in 
the nucleus (Osada & Takahashi, 2007). After nuclear processing of pri-miRNA into 
pre-miRNA and subsequent export, pre-miRNAs are cleaved by Dicer/TRBP into 
(imperfectly matched) miRNA duplexes and the guide strand is incorporated into the 
RISC. The following gene silencing, which either relies on translational repression 
due to the formation of imperfect hybrids between the miRNA and the 3‟-untranslated 
region (3‟ UTR) of the target mRNAs or on deadenylation and subsequent mRNA 
degradation (Fabian et al., 2010), is believed to regulate approximately 30% of the 
genes in the human genome (Osada & Takahashi, 2007). 
RNAi has already proven itself extensively in vitro and several drug candidates 
based on RNAi are also currently under clinical investigation, with targets such as the 
vascular endothelial growth factor and its receptor as a therapy for age-related 
macular degeneration (AMD) (Davidson & McCray, 2011), the viral nucleocapsid of 
respiratory syncytial virus (RSV) (Vaishnaw et al., 2010), and silencing of 
ribonucleotide reductase as a treatment for cancer (Watts et al., 2008; Davis et al., 
2010). 
  
1.2.4 Gene transfer 
 
The classical approach to gene therapy entails replacing a defect gene through the 
introduction of genetic material, frequently in the form of plasmid DNA (pDNA). 
Naturally, the size and polyanionic nature of plasmids imply that delivery vectors are 
an absolute necessity for most applications, although it has been shown that naked 
pDNA administered via intramuscular injection (i.m.) (Wolff et al., 1991), or via 
hydrodynamic injection in a particular therapeutic setting (Zhang et al., 2010), may 
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result in cellular uptake and gene expression (albeit at very modest levels when 
administered i.m.). 
The natural capacity of viruses (e.g. adenoviruses, retroviruses, or lentiviruses 
(Waehler et al., 2007)) to convey genetic material into host cells has traditionally 
been exploited in gene therapy settings, as a means to efficiently introduce a gene of 
interest into a target cell. Although a highly efficacious strategy, virus-mediated gene 
delivery may suffer from issues of questionable patient safety, for instance as an 
implication of the risk of transferring replication-competent viral particles, the risk of 
insertional mutagenesis (i.e. tumor induction), or the induction of severe immune 
reactions (Lundin et al., 2009). Hence, even though the majority of clinical trials 
carried out within the gene therapy field so far has been exploiting viral vectors 
(Edelstein et al., 2007), alternative, non-viral approaches for the transfer of genetic 
material in the form of pDNA have also been developed. These non-viral strategies 
can generally be divided into physical and chemical methods, but only chemical 
delivery vehicles will be discussed within the framework of this thesis. 
 
1.2.5 Chemically modified oligonucleotides 
 
Despite the specificity and versatility of oligonucleotide-mediated gene regulation as 
a therapeutic approach, the inherent characteristics of nucleic acid-based compounds 
are not optimal from a pharmacokinetic point of view. RNA, for instance, is highly 
vulnerable to nuclease activity (Behlke, 2008), leading to a half-life in serum of 
around 2 minutes for unmodified siRNA administered intravenously (Morris et al., 
2005). Furthermore, as a result of the polyanionic nature of oligonucleotides, their 
ability to cross cellular membranes is very limited. These electrostatic properties also 
lead to extensive hydration and reduced binding to serum proteins, resulting in rapid 
systemic clearance through the kidneys (Behlke, 2008; Watts et al., 2008). Finally, 
dsRNA molecules have a propensity to elicit immune responses, primarily mediated 
by the innate immune system. The presence of dsRNA in the cytoplasm is often an 
indicator of viral infection, typically inducing an anti-viral type-1 interferon response 
(Schlee et al., 2006; Robbins et al., 2009). Immunorecognition of RNA depends on 
specific molecular characteristics, such as length, single- or double-strand, sequence 
motifs, and nucleoside modifications, and this recognition is mediated by three 
members of the Toll-like receptor (TLR) family, as well as by cytosolic RNA-binding 
proteins and helicases (Schlee et al., 2006; Robbins et al., 2009).  
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Synthetic oligonucleotides are often divided into first and second generation, 
depending on the backbone modification. One typical representative of first 
generation nucleic acid analogues is the phosphorothioate DNA, where the 
phosphodiester (PO) linkage has been replaced by a phosphorothioate (PS), which 
increases serum stability significantly and prolongs circulation times through its 
„sticky‟ interaction with serum proteins (Spitzer & Eckstein, 1988; Campbell et al, 
1990; Levin, 1999). Oligonucleotides of the second generation has 2‟-O 
modifications, such as 2‟-O-methyl or 2‟-O-methoxethyl RNA, displaying greater 
affinity to RNA but, unlike first generation DNA analogues, do not recruit RNase H 
(Monia et al., 1993). Another commonly used synthetic analogue of the second 
generation is the peptide nucleic acid (PNA), a non-ionic, achiral, DNA analogue in 
which the PO backbone is replaced by 2-aminoethyl-glycine linkages (Nielsen et al., 
1991). The nucleotide bases are attached to this backbone 
at the amino nitrogen, using a methyl carbonyl linker. 
These features render PNA resistant to chemical and 
enzymatic cleavage, it does not recruit RNase H, and its 
hybrid complexes exhibit extraordinary thermal stability 
(Ray & Nordén, 2000). 
The ability of an oligonucleotide to engage in cellular 
pathways, be it through RISC-mediated cleavage or 
through RNase H recruitment, is an important parameter 
to take into account when selecting chemical 
modifications for different applications. When aiming to 
restore correct splicing, the recruitment of ribonucleases is 
naturally highly undesirable, since the mRNA is to remain 
intact after the splice-switching process. However, in for 
instance an RNAi setting, it is naturally crucial that any 
nucleotide modifications are introduced judiciously, in 
order not to interfere with the complex RISC-mediated 
silencing, and any synthetic nucleotide analogues should 
hence be selected accordingly. 
 
Figure 2. PNA 
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Figure 3. Commonly used RNA modifications. Native RNA is pictured on the top left. In the 
phosphorothioate (PS)-RNA a non-bridging oxygen atom is replaced by a sulfur atom; the 2‟-O-methyl 
(2‟-OMe) RNA is methylated on the 2‟-OH moiety; the locked nucleic acid (LNA) has a methylene 
bridge linking the 2‟-O and the 4‟-C, locking the ribose ring into a 3‟-C endo (North) conformation; 
the unlocked nucleic acid (UNA) lacks a bond between the 2‟-C and the 3‟-C atoms; and, in the fluoro 
(F)-RNA a fluorine atom is replacing the 2‟-OH residue. 
 
1.3 DELIVERY VECTORS 
 
The low bioavailability and unfavorable pharmacokinetics of nucleic acid-based 
agents have spurred the development of a variety of different physical, chemical, and 
viral approaches for enhancing delivery. The physical methods, which rely on the 
application of a physical force to enable the oligo- or polynucleotide to penetrate the 
plasma membrane, include needle injection, gene gun, electroporation, and 
hydrodynamic delivery (extensively reviewed by Gao and colleagues (Gao et al., 
2007)), whereas the chemical means frequently involve, for instance, lipid-based 
material, cationic polymers, or peptide-based carriers (Wang et al., 2010; Xu & 
Anchordoquy, 2011). 
As discussed above in connection with gene transfer, the most efficient 
transfection approach is based on a biological system, namely viral vectors that infect 
the target cell. The major drawback of viral delivery stems from the potential 
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immunogenicity and risk for viral recombination (Gao et al., 2007), and furthermore, 
viral systems are not a viable option for transient delivery of short oligonucleotides. 
Although suitable for certain applications, viral delivery is, as is physical delivery 
methods, relatively laborious and as a result, numerous non-viral, chemical vectors 
are undergoing both preclinical and clinical evaluations in different settings. The two 
most commonly applied techniques for oligo- and polynucleotide delivery in vitro are 
based on the packaging of the nucleic acid by lipid-based agents or cationic polymers. 
Lipofection, i. e. non-covalent packaging of nucleic acids (e.g. DNA, as in the 
seminal publication) into small nuclease-protected liposomes, was first described by 
Felgner and colleagues in 1987 (Felgner et al., 1987), and this technique has been 
optimized and commercialized into mainstay transfection reagents for various 
purposes. Cationic liposomes and other forms of lipid-based materials facilitate 
endocytic cellular uptake and promote release from endosomal structures in vitro 
(Gao et al., 2007), and great strides have recently been made, perhaps primarily 
within the RNAi field, with lipid-based nanoparticles in preclinical and clinical trials 
against various therapeutic indications (Morrissey et al., 2005; Akinc et al., 2008; 
Abrams et al., 2010; Semple et al., 2010). 
Cationic polymers constitute another class of commonly utilized transfection 
reagents for oligo- and polynucleotide delivery. Poly(ethyleneimine) (PEI) is 
probably the most extensively used polymer (Boussif, 1996), but it possesses the 
undesirable property of being non-biodegradable (Kunath et al., 2003). However, 
numerous biodegradable polymers, for instance chitosan (Lee & Mohapatra, 2008) 
and polylysine (Laemmli, 1975), are also being exploited for delivery of various types 
of nucleic acid-based agents, and the flora of polymer-based delivery vectors is 
constantly expanding. 
A certain type of short, cationic or amphipathic peptides, belonging to a category 
termed cell-penetrating peptides (CPPs) or protein transduction domains (PTDs), are 
increasingly utilized for delivery of oligonucleotides and plasmids, both in vitro and 
in vivo. CPPs provide an efficient and often non-toxic way of transporting not only 
oligo- and polynucleotides but in fact most types of conceivable macromolecules into 
cells (EL Andaloussi et al., 2005).  
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1.3.1 Non-viral delivery agents 
 
As an initial remark, it is worth noting that the determinants behind a successful non-
viral delivery vector differ significantly depending on whether one is studying in vitro 
transfection of mammalian cells or in vivo delivery of a potential therapeutic agent, and, 
interestingly, there need not be any direct correlation between the two settings (Chang 
et al., 2007; Viola et al., 2009). Further divisions can also be identified within these 
two different contexts, with different cell lines (particularly adherent and suspension 
cell lines) placing different demands on a transfection reagent, and with for example 
different therapeutic indications, target tissues, therapeutic agents, and administration 
routes requiring different delivery vector properties in vivo.  
Although highly variable, a few parameters are frequently discussed in the context 
of delivery of gene-regulating agents, namely nanoparticle size (suitably ranging from 
approximately 50 nm to 200 nm) and surface charge (often referred to as zeta (ζ) 
potential, a parameter that preferably ranges from -10 to + 10 mV) (Tong et al., 2009). 
The physical dimensions have obvious implications for aspects such as 
pharmacokinetics, internalization pathways, and biodistribution, whereas zeta potential 
is crucial for the colloidal stability of a nanoparticle suspension, as well as for both 
pharmacokinetic and pharmacodynamic behavior. 
 
1.3.1.1. Cell-penetrating peptides (CPPs) 
 
In the late 1980s it was realized that the Transactivator of transcription (Tat) protein 
of HIV-1 could translocate across the plasma membrane (Green & Loewenstein, 
1988), and further studies revealed that merely a short stretch of amino acids was 
sufficient to promote membrane translocation (Vivés et al., 1997). In between these 
two discoveries, the group of Alain Prochaintz observed that the 60 amino acid 
homeodomain of the Antennapedia protein, from the fruit fly Drosophila, internalized 
into cells (Joliot et al., 1991), and that this activity was mediated by the third helix of 
the protein (Derossi et al., 1994). With this discovery, the CPP field was born and 
today numerous protein-derived as well as synthetic CPPs have been identified and 
designed.  
The ability of CPPs to transport cargoes of various natures into cells has generated 
substantial interest from both a drug delivery perspective and from a more general 
research standpoint, and consequently CPPs are currently evaluated as delivery 
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vehicles for biologics, oligonucleotides, and small-molecule drugs, and utilized as 
research tools within various fields. 
There is currently no exact definition of CPPs but they are generally below 30 
amino acids in length and display a positive net charge at physiological pH, a feature 
which is important for the cell-penetrating properties. Most CPPs have none, or few, 
negative charges but the presence of acidic amino acids does not necessarily prevent 
internalization (Zorko & Langel, 2005). In addition to cationic amino acids, 
hydrophobic residues are found in most CPPs, perhaps with the exception of the 
homopolymeric polyarginine (Rothbard et al., 2000) and polylysine (Zhou et al., 
1991). Cell-penetration has also been suggested to be intimately associated with 
structural polymorphism, i. e. the ability to change conformation in response to 
changes in the surrounding, for instance medium hydrophobicity or partner diversity 
(Deshayes et al., 2008; Konate et al., 2010). It has for instance been shown that 
monomorphic truncation analogues and mutants of the two commonly utilized CPPs 
penetratin and transportan (TP) display no cell-penetrating properties, indicating that 
structural flexibility may be a key component for efficient cell-penetration (Deshayes 
et al., 2008). 
CPPs are commonly classified according to origin, with the three main categories 
being protein-derived, model, and designed CPPs (Zorko & Langel, 2005). Protein-
derived CPPs are usually comprised of the minimal effective sequence of a 
translocation protein, whereas model peptides and designed CPPs generally originate 
from a rational design approach. Furthermore, CPPs can be classified based on their 
chemical properties, for instance in categories such as polycationic and primary or 
secondary amphipathic peptides (Howl et al., 2007). These categories naturally 
overlap, with the designed chimeric CPP transportan (Pooga et al., 1998) being a 
secondary amphipathic peptide, and the polycationic penetratin being, as mentioned 
above, protein-derived (Derossi et al., 1994).  
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Table 1. CPPs studied in this thesis. 
 
Peptides are C-terminal free acids unless stated otherwise. a Originally with a free acid C-terminally 
but later shown also to have CPP properties when amidated. b C-terminal cysteamide group. 
 
The internalization mechanisms of CPPs have caused great controversy, with the 
main dichotomy being whether the uptake is endocytic or not. It was previously 
commonly accepted that internalization did not involve endocytosis, until 
publications from separate groups revealed that conclusions regarding the 
translocation mechanisms could be based on artifacts in the experimental setup 
(Lundberg & Johansson, 2001; Richard et al., 2003). Although some groups have 
been reporting on non-endocytic internalization for certain peptides, especially at 
high concentrations (Duchardt et al., 2007; Kosuge et al., 2008), even after the 
realization that the energy-independent internalization paradigm may have been 
flawed (Thorén et al., 2003; Christiaens et al., 2004; Duchardt et al., 2007) the 
majority of studies are now emphasizing the importance of endocytosis in the uptake 
CPP Sequence Reference 
Protein-derived 
Penetratin RQIKIWFQNRRMKWKK a Derossi et al., 
1994 
Tat (48-60) GRKKRRQRRRPPQ Vivés et al., 
1997 
pVEC LLIILRRRIRKQAHAHSK-amide  Elmquist et 
al., 1998 
M918 MVTVLFRRLRIRRASGPPRVRV-amide EL Andaloussi 
et al., 2007a 
Designed/model peptides 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL-amide Pooga et al., 
1998 
TP10 AGYLLGKINLKALAALAKKIL-amide Soomets et al., 
2001 
MAP KLALKLALKALKAALKLA-amide Oehlke et al., 
1998 
Arg9 RRRRRRRRR
 Futaki et al., 
2001 
MPG GALFLGWLGAAGSTMGAPKKKRKVb Morris et al., 
1997 
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of CPPs (Nakase et al., 2004; Letoha et al., 2005; EL Andaloussi et al., 2007b). 
However, as an exception to the rule, in a recent report a secondary amphipathic 
peptide was shown to convey siRNA into a wide variety of cell lines via a seemingly 
endocytosis-independent pathway mediated by the interaction between aromatic 
tryptophan residues on the CPP and membrane components (Crombez et al., 2009). 
Most reports evaluating CPP uptake mechanisms have investigated the Tat peptide, 
either per se or conjugated to various cargo molecules (Fittipaldi et al., 2003; Richard 
et al., 2005). Internalization mechanisms of CPPs are generally assessed by 
employing different endocytosis inhibitors that act by selectively blocking particular 
endocytosis pathways, or through the use of fluorescently labeled pathway-specific 
tracers that are analyzed for co-localization with peptides. The results for the Tat 
peptide are divergent and, depending on study, the uptake has been ascribed classical 
clathrin-mediated endocytosis (CME) (Richard et al., 2005), lipid raft/caveolae-
mediated endocytosis (Fittipaldi et al., 2003), macropinocytosis (Wadia et al., 2004; 
Gump et al., 2010), or a combination thereof (Duchardt et al., 2007). This divergence 
can in part be explained by the fact that different cargo molecules have been used, 
indicating that the chemical nature of the entire complex influences the uptake 
mechanism, but internalization pathways may also vary with cell type and CPP 
concentration. Consequently, it comes as no surprise that different CPPs exploit 
different internalization mechanisms for uptake. A newly discovered CPP, termed 
M918, derived from the tumour suppressor protein p14ARF, has been shown to 
primarily exploit the macropinocytic pathway in internalization when conjugated to 
splice-correcting PNA (EL Andaloussi et al., 2007a), whereas, for instance, the 
chimeric transportan (TP) is believed to utilize clathrin-mediated endocytosis (CME) 
for internalization (Padari et al., 2005). 
The initial adherence of CPPs to cells is generally considered to be highly 
dependent on cell surface-anchored proteoglycans (PGs), predominantly 
glucosaminoglycans (GAGs) and particularly heparan sulfates (HS) (Poon & Gariépy, 
2007). The high negative charge densities of the PGs mediate electrostatic 
interactions with the polycationic CPPs, a crucial event prior to endocytic 
internalization. GAG-deficient cells (Console et al., 2003), and particularly cells 
lacking HS (Nakase et al., 2007), exhibit a substantially decreased uptake, results that 
are further supported by the notion of PGs as accessory proteins in endocytosis 
(Belting, 2003). The picture is however far from clear, with a recent report showing 
that the Tat peptide traverses the cell membrane in a HS-independent manner, 
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whereas protease-catalyzed removal of cell surface proteins decreased Tat 
internalization considerably (Gump et al., 2010), indicating an important role played 
by membrane-anchored polypeptides as cellular interaction partners for CPPs. 
The involvement of endocytosis in the uptake of CPPs have fuelled some concerns 
regarding the utility of these vectors in drug delivery (Foerg & Merkle, 2008) and 
endosomal release is often considered to be the rate-limiting step in CPP-mediated 
delivery (Wadia et al., 2004; Said Hassane et al., 2010). As an implication, numerous 
strategies have been developed in order to promote endosomal escape of CPP-based 
carriers, for instance the introduction of a lipid-destabilizing viral domain (Wadia et 
al., 2004), the design of fusogenic CPPs (Lundberg et al., 2007), and the rational 
incorporation of chloroquine-analogues into stearylated transportan 10 (EL 
Andaloussi et al., 2010). 
CPPs have been utilized as delivery agents for various nucleic acid-based agents 
ever since the first example, an antisense oligonucleotide against amyloid precursor 
protein (APP), appeared in 1995 (Allinquant et al., 1995). Subsequently, CPPs have 
been exploited for delivery of, for instance, siRNA (Eguchi et al., 2009; EL 
Andaloussi et al., 2010) and splice-correcting oligonucleotides (Moulton et al., 2003; 
Yin et al., 2011), using either a non-covalent approach based on electrostatic and/or 
hydrophobic interactions (Simeoni et al., 2003; Crombez et al., 2009; EL Andaloussi 
et al., 2010) or covalent conjugation (Pooga et al., 1998; Bendifallah et al., 2006; Yin 
et al., 2011). 
A number of novel, modified CPPs have relatively recently been introduced for the 
delivery of splice-correcting oligonucleotides with various nucleotide chemistries. 
Penetratin with an addition of six arginine residues (R6-penetratin) and octaarginine 
repeatedly interrupted by the hydrophobic spacer 6-amino hexanoic acid have proved 
to promote efficient delivery of both PNA and morpholino oligonucleotides for splice 
correction (Abes et al., 2006; Abes et al., 2007). Not only is splice correction an 
appealing pharmaceutical platform, but as an implication of the nucleolar localization 
of the splicing machinery, delivery of splice-correcting oligonucleotides provides an 
elegant way of assessing CPP-mediated internalization in a functional context.  
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Table 2. CPP-delivered splice-correcting oligonucleotides. 
CPP Oligonucleotide Pre-mRNA target Reference 
MAP PNA Luciferase Wolf et al., 
2006 
(RXR)4 Morpholino Dystrophin McClorey et 
al., 2006 
R6-penetratin Morpholino Luciferase Abes et al., 
2007 
Tat PNA Luciferase Shiraishi et 
al., 2006 
Pip2 PNA Dystrophin Ivanova et al., 
2008 
 
 
1.3.1.1 Cationic polymers 
 
Due to the negative electrostatic potential of nucleic acid-based agents and of most 
synthetic nucleotide analogues (with the exception of peptide nucleic acids (PNAs) and 
phosphoroamidate morpholinos (PMOs)), chemical delivery vectors frequently display 
a net positive charge at physiological pH, in order to facilitate charge interaction with 
the polyanionic nucleic acid cargo. Cationic polymers commonly employed within 
gene transfer or in the delivery of synthetic oligonucleotides include 
poly(ethyleneimine) (PEI) (Boussif et al., 1995), cationic dendrimers (for instance 
poly(amidoamine)), 2-dimethyl(aminoethyl) methacrylate, or various forms of cationic 
polysaccharides such as chitosan or, as in the recent high-impact report on siRNA 
delivery, derivatized cyclodextrin (Davis et al., 2010). 
The process for obtaining the nanoparticle-like delivery complexes (often termed 
„polyplexes‟) generally involves condensing the nucleic acid cargo with the cationic 
polymer, using protocols of varying degree of complexity. Polyplex formation depends 
on a number of parameters, notably the condensation procedure per se, the ionic 
strength of the solution, the order of addition, and the charge and molar ratio of cationic 
polymer to nucleic acid cargo, and the resulting nanoparticles may consequently exhibit 
significantly different properties. 
Complexation of plasmid DNA with, by way of illustration, the amine-containing 
hydrocarbon polymer poly(ethyleneimine) (Boussif et al., 1995), a mainstay in vitro 
transfection reagent, is for instance heavily influenced by the molecular weight of the 
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polymer, the so called nitrogen/phosphate (N/P) ratio (i.e. the ratio between nitrogen 
atoms on the PEI and nucleic acid phosphate groups), which in turn depends on 
whether the polymer is linear (Choosakoonkriang et al., 2003) or branched (Gebhart & 
Kabanov, 2001), as well as the ionic strength of the formulation solution (Tros de 
Ilarduya et al., 2010). PEI-mediated condensation, a process that is generally more 
efficient using PEI with high molecular weight and high charge density (Tros de 
Ilarduya et al., 2010), decreases DNA volume considerably (Choosakoonkriang et al., 
2003) and the size of the resulting PEI/DNA nanoparticles may naturally be an 
important parameter behind delivery efficacy, both in vitro and in vivo.  
In analogy with the highly diverse set of vectors categorized as CPPs, the plethora of 
cationic polymers used for delivery of gene-regulating agents appear to utilize different 
endocytic internalization processes as a way of conveying the nucleic acid cargo into 
the intracellular milieu. Although a positive surface charge has long been viewed as 
facilitating the interaction with the negatively charged proteoglycans on the cell surface 
(Behr et al., 1989), the subsequent endocytic uptake pathways diverge, unsurprisingly, 
depending on aspects such as cell type and polymer characteristics, etc. (Tros de 
Ilarduya et al., 2010). However, cationic polymers are commonly assumed to, one way 
or another, promote release of the nucleic acid cargo from endosomal compartments 
through the so called „proton sponge‟ effect (Pollard et al., 1998). The proton sponge 
effect essentially relies on the fact that the decreasing pH in endosomal compartments 
leads to a higher proportion of protonated nitrogen atoms in the cationic polymer, 
generating a charge gradient that induces an influx of chloride ions leading to osmotic 
swelling and finally endosomal rupture (Akinc et al., 2005).  
In order to further increase the utility of cationic polymers, including PEI, as nucleic 
acid delivery vehicles in vivo, covalent modification of the polymers with 
poly(ethyleneglycol) (PEG) is frequently employed, masking the often positive surface 
charge of the polyplexes. PEGylation of PEI has been shown to not only enhance 
stability of PEI/DNA complexes but also to reduce toxicity and significantly prolong 
circulation times, by decreasing interaction with blood components and non-specific 
accumulation in the liver after intravenous administration (Wolfert et al., 1996; Sung et 
al., 2003; Merdan et al., 2005). PEG is also often included as a component in other 
types of delivery vectors, and the stealth properties it bestows to different vehicles have 
been crucial for the impressive existing preclinical and clinical pipeline of polymer and 
lipid-based delivery vectors (Morrissey et al., 2005; Zimmerman et al., 2006; Davis et 
al., 2010).  
 22 
Although stealth properties and favorable pharmacokinetics are important aspects 
for the in vivo performance of any type of delivery system it is sometimes necessary to 
utilize targeting strategies to attain relevant pharmacological effects. Targeting of a 
nano-sized delivery system to a cell type or tissue of interest can essentially be 
classified as either passive or active. Passive targeting relies on various manifestations 
of the underlying pathophysiology of the disease to be treated, with cancer being the 
textbook example, whereas active targeting is accomplished with the use of ligands 
interacting with a receptor on the target cell.  
Solid cancer tumors exhibit tissue characteristics that are not observed in normal 
tissues or organs, namely defective vascular architecture, impaired lymphatic drainage, 
increased production of permeability mediators, such as various matrix 
metalloproteinases, and increased blood supply (Matsumura & Maeda, 1986; Maeda et 
al., 2000), leading to accumulation of nano-sized particles, for instance polyplexes and 
lipoplexes, in the tumor tissue. This phenomenon is termed the enhanced permeability 
and retention (EPR) effect and it implies that solid tumors are in fact passively targeted 
by most nanoparticle-like delivery vectors, a feature that can be exploited both for the 
delivery of gene-regulating agents and for chemotherapy delivery. 
Active targeting, in contrast, entails incorporating a targeting ligand, with affinity for 
a receptor up-regulated on a cell type of interest, into a delivery vector. In a recent 
report on evidence of RNAi in humans from systemically administered siRNA-
containing nanoparticles a transferrin ligand was utilized, in order to target the 
cyclodextrin-based vector to solid cancers refractory to standard-of-care therapies 
(Davis et al., 2010). However, the use of transferrin was pioneered in a polyplex 
context already back in 1997, when the group of Ernst Wagner covalently conjugated 
transferrin or an anti-CD3 antibody to PEI (Kircheis et al., 1997), thereby improving 
plasmid delivery considerably. Targeting ligands are nowadays a mainstay strategy for 
delivery of gene-regulating agents, and successful targeted polyplex delivery has been 
reported using for instance vitamins (notably folate (Hwa Kim et al., 2006)), peptides 
(Ke et al., 2009; Kim et al., 2011), and saccharides (Nie et al., 2010). 
 
1.3.1.2 Lipid-based material 
 
Lipid-based nucleic acid delivery vehicles have not been researched in any greater 
detail within the framework of this thesis, wherefore only a short account of their 
properties and applications will follow. 
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Liposome transfection was pioneered already back in 1987 (Felgner et al., 1987) and 
today lipid-based platforms, comprising for instance a combination of an ionizable 
lipid, a neutral lipid, cholesterol, and a PEG lipid (Morrissey et al., 2005; Zimmerman 
et al., 2006), constitute state-of-the-art within the delivery of gene-regulating agents, 
particularly siRNAs (Morrissey et al., 2005; Zimmerman et al., 2006; Abrams et al., 
2010; Semple et al., 2010).  
Interestingly, capitalizing on the often modular nature of lipid-based delivery 
vehicles, the group of Robert Langer at MIT has adopted a combinatorial approach to 
developing lipid-based materials for delivery of gene-regulating agents, a strategy that 
has not only generated promising delivery data in various disease models but that has 
also resulted in proposed design criteria for lipid-based delivery materials (Akinc et al., 
2008; Frank-Kamenetsky et al., 2008; Love et al., 2010). 
Though great strides have been made with lipid-based delivery vectors, particularly 
within the RNAi field where low doses of lipid-formulated siRNAs have resulted in 
sustained gene silencing (Akinc et al., 2008; Frank-Kamenetsky et al., 2008; Love et 
al., 2010), their utility is to date almost exclusively limited to liver targeting, although 
at least one corporate player within the RNAi sector has been releasing information on 
successful siRNA delivery beyond the liver, notably to the vascular endothelium and to 
immune cells (Alnylam Pharmaceuticals, 2010). However, lipid-induced toxicity has 
been reported to constitute a significant hurdle for pharmaceutical development (Filion 
& Philips, 1998), meaning that there may be a bumpy road to clinical impact, despite 
the promising research presented to date.  
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2 AIMS OF THE STUDY 
 
The research presented in this thesis spans the fields of cationic polymer- and CPP-
mediated delivery of gene-regulating oligonucleotides and plasmid DNA, with 
specific foci on (i) internalization mechanisms of a number of different CPPs 
conjugated to synthetic splice-correcting oligonucleotide analogues, as a means of 
delineating the endocytic internalization pathways of these short peptide vectors, (ii) 
development of a rationally designed chemically modified CPP with enhanced 
delivery properties, and (iii) the design of a novel cationic polymer vector for delivery 
of small interfering RNAs (siRNAs). The main aims of the respective papers are 
presented below: 
 
Paper I: The aim of this paper is to determine whether the delivery efficacy of 
conjugates between various CPPs and splice-correcting PNA correlates with the 
chemical nature of the CPP. Furthermore, the study is aiming at characterizing 
possible differences in internalization mechanisms of polycationic and amphipathic 
CPPs. 
 
Paper II: The objective of this study is to investigate whether chemical 
modification, specifically stearylation, enhances CPP-mediated delivery of splice-
correcting PS 2‟-O-Me RNA oligonucleotides, using a non-covalent co-incubation 
approach. 
 
Paper III: The aim of this paper is to evaluate the utility of the stearylated CPP 
TP10, identified in paper II, in the context of plasmid delivery in vitro and in vivo. 
Moreover, the study aims at characterizing the nanoparticles formed between 
stearylated TP10 and plasmid DNA (pDNA) from a physical perspective, as well 
as assessing the immunological impact, in cell culture and in mice, of the 
CPP/pDNA complexes. 
 
Paper IV: The objective of this paper is the development and characterization of 
an entirely novel class of polymeric vectors, so called polythiophenes, for delivery 
of siRNA. Furthermore, the study intends to assess toxicological aspects relating to 
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the polythiophene-mediated siRNA delivery, as well as to shine light on possible 
internalization pathways. 
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3 METHODOLOGICAL CONSIDERATIONS 
 
The methods utilized in this thesis are thoroughly described in each paper. Hence, 
merely some theoretical and practical aspects pertaining to methods and techniques of 
particular importance for the research will be discussed herein. 
 
3.1.1 Solid-phase peptide and oligonucleotide synthesis  
 
All peptides and PNAs used in this thesis were synthesized using solid-phase peptide 
synthesis (SPPS) methodology, a groundbreaking invention introduced by Bruce 
Merrifield in 1963 (Merrifield, 1963), resulting in paradigm shift within the peptide 
synthesis field. SPPS is based on repeated cycles of coupling and deprotection of 
protected amino acids, carried out on a solid support. Peptides and PNAs used in 
papers I and II were assembled by t-Boc chemistry using a 4-
methylbenzhydrylamine-polysterene (MBHA) resin, generating C-terminally 
amidated peptides. The loading of resin for peptide synthesis was 1.16 mmol/g while 
the loading for PNA synthesis was substantially lower (0.1 mmol/g) as a result of the 
bulky nature of PNA monomers. Amino acids were coupled as hydroxybenzotriazole 
(HOBt) esters while PNA monomers were coupled with 2-(7-aza-1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU).  
Peptides and PNAs were cleaved from the resin using anhydrous hydrogen 
fluoride. To minimize side-reactions of reactive carbocations formed during cleavage, 
p-cresol, and if the peptide or PNA contained sulfur, p-thiocresol, was added to the 
cleavage mixture to act as scavengers. Following cleavage and extraction, peptides 
and PNAs were filtrated to remove the resin and subsequently freeze-dried. Crude 
products were purified using semi-preparative reversed-phase (RP) high performance 
liquid chromatography (HPLC) and analyzed using a matrix-assisted laser 
desorption/ionization-time of flight (MALDI–TOF) mass spectrometer (MS). 
For covalent conjugation to PNA, peptides were synthesized with a cysteine 
residue having a 3-nitro-2-pyridinesulfenyl (Npys) group whereas the PNA contained 
a normal cysteine. Peptides and PNA were mixed in 20% acetonitrile/water, 
containing 0.1% trifluoroacetic acid (TFA), and stirred over night. Conjugates were 
purified and analyzed as described for peptides and PNAs. 
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The peptides studied in paper III were, in contrast, synthesized by 
fluorenylmethyloxycarbonyl (Fmoc) SPPS, using a Rink-amide 
methylbenzylhydrylamine resin to obtain C-terminally amidated peptides. Unlike t-
Boc chemistry, Fmoc-based SPPS does not necessitate the use of hydrogen fluoride to 
cleave the peptides from the resin, wherefore Fmoc is generally considered a safer 
alternative. Again, peptides were purified using RP-HPLC and analyzed using 
MALDI–TOF MS. 
Synthesis of PS 2-O-Me RNA was performed using disposable columns packed 
with polystyrene-based solid support, functionalized for synthesis of oligonucleotide 
sequences with 2-O-Me RNA monomers at the 3‟-end. 5‟-labelling was carried out 
using Cy5 amidite. Crude oligonucleotides were purified by anion exchange 
chromatography (AEC), desalted, and freeze-dried. 
 
3.1.2 Covalent and non-covalent strategies for cargo attachment 
 
In paper I, the splice-correcting PNA cargo was covalently coupled to the CPPs using 
a reducible disulfide bridge. The rationale behind utilizing this strategy is that the 
intracellular glutathione-mediated cleavage of the disulfide bond releases the cargo 
inside the cell (Hällbrink et al., 2001), avoiding possible target interference. 
Additionally, this strategy produces well-defined chemical entities, which is 
advantageous for future potential therapeutic applications. However, the strategy is 
rather laborious, requiring extensive purification both prior to and after conjugation.   
The non-covalent co-incubation strategy utilized in papers II-IV essentially only 
entails a simple mixing of the delivery vector and the nucleic acid cargo at a specified 
(molar or charge) ratio, resulting in the formation of nanoparticle complexes. The 
basis for the complex formation is believed to be predominantly reliant on 
electrostatic interactions between the polycationic agents and the polyanionic 
oligonucleotides, or oligonucleotide analogues, although it is likely that there is also a 
bond component originating from hydrophobic interactions. Naturally, an uncharged 
oligonucleotide, like PNA, is not compatible with the electrostatically driven co-
incubation strategy, but the simplicity behind the co-incubation approach, in spite of 
the fact that it is not universally applicable, is nevertheless appealing. Furthermore, 
the co-incubation strategy generally requires smaller amounts of material than 
covalent conjugation, and the resulting nanoparticle complexes often display a high 
degree of serum stability. 
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3.1.3 Splice correction assay 
 
In order to facilitate quantitative assessment of the cellular delivery efficiency of 
antisense oligonucleotides, the group of Ryszard Kole has developed a cellular splice 
reporter system (Kang et al., 1998) making it possible to assay for enzymatic activity 
instead of utilizing, for instance, more cumbersome PCR-based methods. The assay is 
based on HeLa cells stably transfected with a plasmid carrying a luciferase-encoding 
gene, interrupted by intron 2 from β-globin pre-mRNA. The intron contains an 
aberrant splice site that, unless it is masked by an antisense oligonucleotide, activates 
a cryptic splice site, generating non-functional luciferase (Figure 4). Consequently, 
detection of luminescence implies that the splice pattern has been modulated and this 
system is thus a useful indicator for both delivery efficacy and splice correction per 
se. In paper I, this assay was utilized to delineate uptake mechanisms of various 
CPPs, whereas in paper II, the assay verified the potency of the stearylated TP10 for 
non-covalent delivery. 
 
 
Figure 4. Pre-mRNA of the luciferase gene with the β-globin intron. Masking of the aberrant splice site is 
necessary in order to obtain functional luciferase. 
 
3.1.4 Cell culture 
 
The abovementioned cell line (HeLa pLuc 705) was utilized throughout all 
experiments in papers I and II of this thesis. HeLa cells derive from immortalized 
cervical cancer cells taken from a woman named Henrietta Lacks in the early 1950s. 
The cells are robust, grow rapidly, and are rather easy to transfect, making them a true 
medical and biological research workhorse over the past half a decade. In paper III, 
Chinese hamster ovary (CHO), HEK 293, U87, THP1, and U2OS cells were utilized, 
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together with mouse embryonal fibroblasts, whereas paper IV employed U2OS and 
HeLa cells. 
 
3.1.5 Quantitative uptake measurements  
 
Fluorescence-based measurements have traditionally been the mainstay approach for 
rapid CPP evaluation in vitro, both through the use of microscopy and through 
spectrofluorometry. The simplicity and rapid assay procedures are the appealing 
factors behind the widespread usage of fluorescence-based methods, but they are 
associated with certain drawbacks. When using spectrofluorometry it is virtually 
impossible to distinguish between peptides trapped in endosomal compartments and 
peptides inside the cell. As a consequence, the uptake of fluorophore-labeled peptides 
or polymers does not necessarily correlate with the bioactivity of the cargo molecule, 
for instance an oligonucleotide, wherefore it is pivotal to complement these assays 
with other methods.  
The quantitative spectrofluorometry measurements utilized in this study are based 
on fluorescently labeled peptides or cargoes. The CPP constructs are incubated with 
cells for a certain time period, after which the cells are thoroughly washed, treated 
with trypsin, centrifuged, and lysed. Finally, fluorescence is measured and normalized 
to protein content in each well.  
 
3.1.6 Proliferation and cytotoxicity measurements 
 
Most CPPs generally exert limited toxic effects at the concentrations used in this 
study but polyplexes frequently cause toxicity, meaning that cytotoxicity assays are 
indispensable in order to avoid obtaining skewed results from other assays. Long-
term cytotoxicity has been evaluated using, among other methods, the Wst-1 viability 
assay, which assesses proliferation by measuring mitochondrial metabolic activity, or 
more accurately the activity of mitochondrial dehydrogenases. Wst-1 is cleaved by 
the succinate-tetrazolium reductase system, producing the dye formazan, which can 
be spectrophotometrically quantified at 420 nm (Slater et al., 1963). The conversion 
of Wst-1 is in linear correlation with the dehydrogenase activity and consequently the 
viability of the cells. 
Monitoring the integrity of the plasma membrane is pivotal when utilizing CPPs or 
cationic polymers for delivery of various cargoes. If the membrane integrity has been 
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compromised, a typical sign of transient toxicity, lactate dehydrogenase (LDH), an 
enzyme catalyzing the conversion of lactate into pyruvate with simultaneous 
interconversion of NAD
+
 into NADH, can leak out of the cell. Extracellular LDH-
promoted NADH production can be detected via an enzymatic reaction where NADH 
reacts with reazurin and forms resorufin, which can be detected by measuring 
fluorescence at 560ex/590em nm. The LDH leakage assay provides a fast and simple 
assessment of plasma membrane integrity, but as LDH is a rather large protein the 
assay potentially fails to detect small pores created by a delivery vector.    
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4 RESULTS AND DISCUSSION 
 
The first study presented herein utilizes CPP-mediated splice-correcting 
oligonucleotide delivery as an instrument for addressing internalization mechanisms 
of CPPs with different chemical properties. The second study presents a chemically 
modified CPP, stearylated transportan 10 (TP10), for highly efficient delivery of 
splice-correcting oligonucleotides using a non-covalent co-incubation strategy, 
whereas the third paper evaluates the utility of stearylated TP10 in pDNA delivery. 
Finally, the fourth study explores the utility for siRNA delivery of a novel class of 
polymeric vectors, known as polythiophenes. 
 
4.1.1 CPP-mediated PNA uptake depends on the chemical nature of the 
CPP (Paper I) 
 
The uptake mechanisms of CPPs are constantly debated, with different reports 
pointing in diverging directions. This study comprises an efficacy assessment and a 
mechanistic evaluation of seven commonly employed CPPs (Tat, penetratin, 
transportan (TP), transportan 10 (TP10), MAP, M918, and pVEC) using a splice-
correcting PNA oligonucleotide cargo covalently conjugated to the peptides via a 
disulfide bridge. The CPPs originate from two different groups, displaying either a 
high degree of amphipathicity (TP, TP10, MAP, and pVEC) or a polycationic nature 
(Tat, penetratin, and M918).  
No obvious correlation was observed between the chemical nature of CPPs and the 
delivery efficacy, as inferred from the results obtained with the previously described 
splice correction assay. The polycationic CPP Tat and the two amphipathic peptides 
pVEC and MAP were unable to promote significant delivery of the splice-correcting 
PNA, despite exhibiting a substantial quantitative uptake, thus indicating the 
necessity of using a functional assay when evaluating CPP delivery. Interestingly, 
clearly illustrating the discrepancy between uptake and bioactivity, the pVEC-PNA 
conjugate exhibited a very strong dose-dependent quantitative uptake but apparently 
failed to deliver the splice-correcting PNA to the nucleolus, where the spliceosome 
machinery performs its function.   
Moreover, and perhaps slightly surprising at first glance, Tat, arguably the most 
commonly employed CPP, merely exhibited a very weak PNA delivery activity. 
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However, Tat is normally most efficient for delivery of polypeptide-based cargo 
molecules, wherefore its inability to efficiently transport a relatively small PNA 
appears quite logical. Hence it is important to bear in mind that different CPPs have 
different cargo preferences, meaning that the choice of vector must be governed by a 
careful assessment of the delivery properties of the CPP in light of the therapeutic 
application in question. 
Further, the involvement of endocytosis was confirmed through the use of the 
lysosomotropic agent chloroquine (which exerts a „proton sponge‟-like effect on 
endosomes, thereby promoting endosomal release) and through measuring splice 
correction after treating cells at 4° C. As expected, chloroquine decreased the 
quantitative uptake as a result of its impeding effect on endocytosis, but the increased 
splice correction indicated release of material trapped in endosomal compartments. 
Treatment at low temperature also significantly diminished both quantitative uptake 
and splice correction, further corroborating the involvement of endocytic 
internalization processes. 
In order to elucidate the endocytic mechanisms of the CPPs capable of successfully 
delivering the PNA cargo, a number of frequently used endocytosis inhibitors were 
employed. Chlorpromazine, an inhibitor of clathrin-mediated endocytosis (CME), 
significantly decreased the splice correction of the amphipathic peptide (TP and 
TP10) conjugates, whereas splice correction mediated by the polycationic penetratin 
and M918 was reduced when using the macropinocytosis inhibitors wortmannin and 
cytochalasin D. In addition, the ability of the CPPs to promote uptake of the fluid-
phase markers dextran and transferrin further supported the role of distinct 
endocytosis pathways. M918 promoted significant dextran uptake, indicating that 
macropinocytosis is the main internalization mechanism, whereas TP10 induced 
transferrin uptake, confirming CME involvement. 
The stipulated dependence on the extracellular proteoglycan heparan sulfate (HS) 
was assessed through pre-treatment of cells with the enzyme heparinase III, in order 
to remove HS from the cell surface. Splice correction decreased for all the conjugates, 
except M918-PNA, indicating that HS do play an important role prior to endocytic 
internalization. Interestingly, the splice correction mediated by M918 was in fact 
increased when applying heparinase treatment, perhaps suggesting involvement of 
another cell surface component that becomes more accessible when removing HS. As 
shown in a recent report, certain CPPs, specifically Tat (Gump et al., 2010), appear to 
require interaction with a polypeptide component prior to internalization, and one 
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could hypothesize that this is also the case for M918, which itself derives from the 
tumor suppressor protein p14ARF.  
In conclusion, this study demonstrated low correlation between the ability to 
efficiently stimulate uptake of splice-correcting oligonucleotides and the chemical 
nature of the CPPs. However, the chemical characteristics of CPPs appeared to 
influence the employed endocytic internalization mechanism of the conjugates, 
providing additional insights into the parameters dictating CPP internalization.  
 
4.1.2 A stearylated CPP for delivery of splice-correcting 
oligonucleotides (Paper II) 
 
The non-covalent interaction between CPPs and negatively charged oligonucleotides 
is the fundamental factor behind the simplistic co-incubation strategy. Previously, 
two chemical modifications of CPPs, i. e. N-terminal stearylation and C-terminal 
cysteamidation, have been reported to be pivotal for efficient non-covalent delivery of 
oligonucleotides. In this study, N-terminal stearylation was evaluated for transportan 
10 (TP10) and penetratin (Pen), and compared to the previously utilized stearylated 
nona-arginine (Arg9). 
Unmodified CPPs co-incubated with phosphorothioate (PS) 2-O-methyl (2-O-Me) 
RNA did not promote any significant splice correction, despite displaying a 
substantial quantitative uptake. However, when utilizing the lysosomotropic agent 
chloroquine, the splice correction mediated by TP10-delivered PS 2-O-Me RNA 
increased dramatically, potentially indicating substantial endosomal entrapment of the 
PS 2-O-Me RNA/CPP complexes.  
Introducing a C-terminal cysteamide improved the TP10-mediated transfection 
slightly, in fact to a level well above the transfection obtained with the previously 
used cysteamidated CPP MPG, but the increase was still rather modest. 
Consequently, in order to achieve more efficient transfection, all CPPs were N-
terminally stearylated, and co-incubated with the splice-correcting oligonucleotide. 
Stearylated TP10 (TP10-stearyl) proved to be an extraordinarily efficient transfection 
agent, reaching splice correction levels in parity with the effects obtained with the 
commercially available transfection agent Lipofectamine 2000
TM
. The quantitative 
uptake of TP10 increased slightly as an implication of stearylation, but the splice 
correction was increased by approximately a factor thirty, perhaps indicating that 
stearylation has a more substantial impact on endosomal escape than on uptake. 
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Interestingly, stearylation did not have such a pronounced effect on the polycationic 
CPPs penetratin and Arg9, suggesting that the interplay between the amphipathic 
TP10 and the stearyl moiety is crucial for endosomal escape.  
The preserved efficiency in serum and the completely non-toxic behavior of TP10-
stearyl are additional appealing features of this highly efficient delivery vector. These 
characteristics are essential for future in vivo applications, but further investigations 
are needed to verify its utility.  
 
4.1.3 Stearylated TP10 promotes efficient in vitro and in vivo pDNA 
delivery (Paper III) 
 
Encouraged by the efficacious oligonucleotide delivery promoted by the stearylated 
CPP TP10 in paper II, we set out, in this study, to evaluate its utility for the delivery of 
plasmid DNA, both in vitro and in vivo. 
Again employing the non-covalent co-incubation approach, this study initially 
verified, using an ethidium bromide (EtBr) exclusion assay, that stearyl-TP10 had the 
ability to condense pDNA. Stearyl-TP10 promoted packaging of pDNA to a greater 
extent than its non-stearylated counterpart and the stability of the complexes, assessed 
using a heparin displacement assay, was considerably higher when using the stearylated 
TP10. The stearyl-TP10/plasmid nanoparticle complexes were subsequently studied 
using dynamic light scattering (DLS) and these measurements revealed, in accordance 
with the EtBr exclusion assay, that higher charge ratios (CRs) lead to the formation of 
nanoparticles with smaller dimensions. The overall size of the stearyl-TP10/plasmid 
nanoparticle complexes was in the range of 125-150 nm and the zeta (ζ) potential of the 
complexes was shown to range from approximately -5 to -11 mV. 
In vitro experiments initially verified that unmodified CPPs (i.e. TP10 and Arg9) 
were unable to promote significant plasmid transfection in CHO cells, whilst stearyl-
TP10 displayed considerable activity in CHO, U2OS, HEK293, and U87 cells, as well 
as in hard-to-transfect, primary mouse embryonal fibroblasts. A considerable decrease 
in transfection efficacy observed in glycosaminoglycan (GAG)-deficient CHO cells 
clearly pointed toward endocytosis involvement, and endocytic internalization was 
confirmed by co-treatment with the lysosomotropic agent chloroquine, which resulted 
in increasing transfection levels. In light of the condensation properties and the 
similarities between TP/plasmid and stearyl-TP10/plasmid in terms of quantitative 
uptake, as measured by spectroflourometry using fluorescently labeled peptides, this 
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indicates that the presence of the stearyl moiety on stearyl-TP10 most likely 
predominantly enhances delivery through nanoparticle stabilization and through 
promoting endosomal escape, and not by increasing cellular uptake. 
In order to pave the way for in vivo evaluation, the toxicity profile and the immune-
stimulatory effects of stearyl-TP10 were assessed using a cell viability assay and 
interleukin (IL) release measurements, respectively. Encouragingly, stearyl-TP10 did 
not exert any apparent toxic effects at any of the tested CRs and neither did the peptide 
induce release of IL-1β in cell culture or IL-6 in vivo, and based on these results the 
study was progressed into in vivo settings. 
Balb/c mice were injected intramuscularly (i.m.) (into the Musculus tibialis anterior) 
and intradermally (i.d.) with stearyl-TP10/luciferase-encoding plasmid complexes at 
different CRs, and bioluminescence measurements were carried out at days 1, 3, 7, and 
14, and at days 1, 3, and 7, respectively, post-injection. Only stearyl-TP10/pDNA at CR 
1 promoted considerable luciferase expression upon i.m. and i.d. administration, but the 
luciferase expression displayed a dose-dependent increase over a range of from 1 to 10 
µg of plasmid.  
Taken together, stearyl-TP10 proved to be a widely applicable and efficacious 
transfection reagent for in vitro purposes and the fact that the peptide-based vector was 
capable of dose-dependently and sustainably increase gene expression in vivo, in 
combination with complete absence of systemic toxicity and immunogenicity, makes it 
an interesting delivery vector for future utilization, both in vitro and in vivo. 
 
4.1.4 Polythiophenes as a novel class of siRNA delivery vectors (Paper 
IV) 
 
The groundbreaking report of the utility of small interfering RNAs (siRNAs) for 
inducing RNA interference (RNAi) has initiated an extensive search for a magic 
delivery bullet. Although classical nucleic acid-delivery platforms (such as lipoplexes 
and polyplexes) are frequently employed also within the RNAi context numerous 
unconventional agents are being investigated as potential delivery vehicles. This 
study continues along those lines, utilizing a methylated serine-modified 
polythiophene known as POMT (poly(3-[(S)-5-amino-5-methoxycarboxyl-3-
oxapentyl]-2,5-thiophenylene hydrochloride)), a compound to date predominantly 
used in biosensor applications, for the delivery of siRNAs. 
 38 
POMT and its unmethylated, zwitterionic counterpart POWT (poly(3-[(S)-5-
amino-5-carboxyl-3-oxapentyl]-2,5-thiophenylene hydrochloride)) exhibit substantial 
affinities for numerous biomolecules, particularly nucleic acids. Thus, through 
screening a range of molar ratios of an anti-luciferase siRNA to POMT/POWT in an 
in vitro assay, we set out to explore whether POMT and/or POWT could convey the 
siRNA cargo into the cytoplasm of a target cell. Both polythiophenes were in fact 
capable of promoting siRNA-induced silencing of the luciferase reporter gene in 
U2OS cells, but POMT displayed a considerable higher activity, reaching a maximum 
knockdown of approximately 85% using 50 nM siRNA at a molar ratio of 
siRNA:POMT of 1:50. POMT performed well also at lower siRNA concentrations 
(25 nm and 12.5 nM), and POMT-mediated delivery of an unrelated mock siRNA did 
not induce any statistically significant decrease in luminescence output at any 
evaluated molar ratio. 
Nanoparticle tracking analysis (NTA) was subsequently used to assess the size of 
the siRNA:POMT complexes formed by co-incubating the two polyelectrolytes. A 
double-stranded DNA and a POMT analogue called tPOMT has previously been 
shown to form single, well-defined oligomolecular clusters at a molar ratio of 
DNA:tPOMT of 1:2, but in our setup, using molecules with a higher molecular 
weight as well as a higher molar ratio, we detected nanoparticle complexes having 
hydrodynamic diameters ranging from approximately 80 to 90 nm. The size of the 
siRNA:POMT complexes are in a suitable range for many therapeutic applications, 
notably cancer, since the nanoparticles are large enough to avoid first-pass glomerular 
clearance but small enough to diffuse into leaky tumor vasculature (Davis et al., 
2008). 
To further examine the interaction between siRNA and POMT, circular dichroism 
(CD) spectroscopy was used. The CD spectrum of POMT was indicative of a helical 
conformation, likely a function of the presence of supramolecular POMT clusters in 
which the individual polythiophenes are packaged so as to exhibit a helical structure. 
Upon addition of POMT to siRNA (at a molar ratio of 50:1), a slight decrease in 
signal intensity was observed, most likely originating from helicity-disturbing 
interspersion of siRNA with the POMT clusters, thereby confirming the presence of 
supramolecular siRNA:POMT aggregates or nanoparticles. 
Through employing standard assays for endocytosis involvement, the 
internalization mechanism of the siRNA:POMT complexes was investigated. A 
significant decrease in gene silencing was seen when blocking energy-dependent 
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uptake, a result that indicated endocytic internalization, but pre-treatment with 
chloroquine did not, unexpectedly, induce a higher degree of knockdown. Taken 
together, these results point to endocytic internalization of the siRNA:POMT 
complexes but potentially also to efficient endosomal escape. In agreement with this 
hypothesis, live-cell fluorescence microscopy performed after transfection, exploiting 
the inherent optical properties of POMT and using a Cy5-labelled siRNA, detected a 
clear co-localization of siRNA and POMT, both in vesicular structures and in the 
cytoplasm. 
Encouragingly, POMT did not exert any hemolytic effects in an in vitro assay, 
potentially indicating that the polythiophene-based delivery vector could be suitable 
for in vivo evaluation, albeit after further in vitro characterization and delineation of 
its internalization mechanism.  
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5 CONCLUSIONS AND FUTURE PROSPECTS 
 
The main conclusions of the four papers comprising this thesis are presented below. 
 
Paper I: The chemical nature of CPPs does not correlate with efficacy in terms of 
delivery of splice-correcting PNA-based oligonucleotides. However, polycationic 
CPPs appears to primarily utilize macropinocytosis for internalization whereas 
amphipathic CPPs exploit clathrin-mediated endocytosis (CME). 
 
Paper II: The introduction of an N-terminal stearyl moiety on the amphipathic 
CPP transportan 10 (TP10) dramatically improves delivery of splice-correcting 
oligonucleotides, using a non-covalent co-incubation procedure. Furthermore, the 
potency is preserved in serum and the complex displays no cytotoxicity, making it 
a promising vector for future in vivo applications. 
 
Paper III: The stearylated TP10 discovered in Paper II lends itself also to plasmid 
delivery, both in vitro and in vivo. The transfection efficacy of the stearyl-
TP10/plasmid complexes reaches levels in parity with lipofection, but without any 
associated toxicity. Additionally, stearyl-TP10-mediated plasmid delivery results 
in sustained gene expression upon i.m. and i.d. injection into mice, warranting 
further in vivo evaluation. 
 
Paper IV: The cationic polythiophene POMT, but not its zwitterionic counterpart 
POWT, shows great promise as an in vitro delivery vector for siRNA. Further, its 
complete absence of hemolytic activity could potentially render it suitable for in 
vivo siRNA delivery. 
 
In conclusion, this thesis has provided new data regarding the internalization 
mechanisms of CPP conjugates, demonstrating that the chemical nature of the CPP 
appears to influence the endocytic internalization pathway. Furthermore, the thesis 
has introduced a new chemical entity, stearylated transportan 10, for efficient, non-
toxic delivery of splice-correcting oligonucleotides in vitro, and pDNA both in vitro 
and in vivo. Additionally, the research described herein has lead to the identification 
of a novel use for the cationic polythiophene POMT in the delivery of siRNA, 
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potentially implying that polythiophenes as a class may be suitable for drug delivery 
purposes. 
Even though the number of delivery vectors for nucleic acid-based agents has 
soared in recent years, the field appears to be in a seemingly never-ending search for 
a magic delivery bullet. In light of the multifaceted nature of the field this comes as 
no surprise, considering the numerous highly diverse therapeutic approaches to gene 
regulation (antisense, RNAi, splice-correction, and classical gene therapy, just to 
name a few), the almost endless number of „druggable‟ targets, and thereby also the 
vast array of putative disease indications and administration modes. Hence, in spite of 
the plethora of existing delivery vectors for nucleic acid-based agents the non-viral 
delivery field has a clear raison d’être, as an implication of the ad hoc approach often 
needed in a specific therapy or disease context. Although ongoing clinical evaluations 
may provide certain indications as to what works and what does not in relevant 
settings it seems likely that the nucleic acid delivery field will continue to expand 
over the years to come, hopefully in parallel with widespread clinical translation of 
therapeutic platforms for gene regulation, and aided by the continued investigation 
into and development of novel delivery vectors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   43 
6 ACKNOWLEDGEMENTS 
 
The research described in this thesis has been carried out at the Unit for Molecular Cell 
Biology and Gene Therapy Science (MCG), Department of Laboratory Medicine, 
Karolinska Institutet (KI), and at the Department of Neurochemistry, Stockholm 
University (SU), and I am very much indebted to all my colleagues in both 
departments. 
My time as a PhD student has been all but conventional and it would not have been 
possible for me to complete my studies without the help, flexibility, and support of a 
large number of people at the Karolinska Institute, at Stockholm University, but also at 
Albihns.Zacco AB, my employer over the last three years. I started my studies in the 
group of Ülo Langel at SU but after having been on a leave of absence in the corporate 
world I returned to academia to continue my PhD in the group of Ted Smith at KI. I 
would thus naturally like to express my gratitude to Ülo, but perhaps even more to Ted, 
who took me on halfway through my studies with unsurpassed flexibility and support.  
The common denominator throughout my studies has been my good friend and main 
supervisor Samir EL Andaloussi, who initially introduced me to the mysteries of cell-
penetrating peptides at SU and subsequently enabled me to continue my research at KI. 
Very few people can display the same type of excitement and encouragement for a new 
idea or for an interesting piece of result, and this attitude has been a constant source of 
inspiration during my studies. 
I am also indebted to innumerable colleagues-turned-friends at SU, KI, and 
Albihns.Zacco. At SU I would especially like to highlight the friendship, support, and 
help of the oligo wiz Peter G and the Estonian squad comprising Indrek, Imre, and 
Maarja, at KI the Portuguese gang, and specifically my coworkers Joana and Pedro, 
and at Albihns.Zacco my lunch buddies Viktor and Jarkko. Additionally, I owe a lot to 
all the members of the MCG group for teaching me the drills in a new lab, for gladly 
sharing lab benches and equipment, and for just being a great bunch of people. I would 
also like to express a sincere thank you to all my friends outside work (not that many 
left after these years, perhaps!), in particular the KTH bunch (you know who you are!) 
and my good old friends Richard, Peter, Hanna, and Filip, for occasionally making it 
possible for me to forget about such trifling things as science and intellectual property. 
 44 
Finally, my deepest gratitude goes to my parents, my sister Sofia, farmor, and my 
beloved girlfriend Nikki; words cannot begin to express how much you all mean to me. 
You are my world.  
 
   45 
7 REFERENCES 
 
Abes, S., Moulton, H. M., Clair, P., Prevot, P., Youngblood, D. S., Wu, R. P., Iversen, P. L., Lebleu, B. Vectorization of 
morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. 
J Control Release 116, 304-313 (2006). 
 
Abes, S., Turner, J. J., Ivanova, G. D., Owen, D., Williams, D., Arzumanov, A., Clair, P., Lebleu, B. Efficient splicing 
correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 35, 4495-4502 (2007). 
 
Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., 
Davide, J. P., Burke, P. A., Sachs, A. B., Stirdivant, S. M., Sepp-Lorenzino, L. Evaluation of efficacy, biodistribution, and 
inflammation for a potent siRNA nanoparticle: effect of dexamethasone cotreatment. Mol Ther 18, 171-80 (2010). 
 
Akinc, A., Thomas, M., Klibanov, A. M., Langer, R. Exploring polyethyleneimine-mediated DNA transfection and the proton 
sponge hypothesis. J Gene Med 7, 657-663 (2005).  
 
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., 
Alvarez, R., Borodovsky, A., Borland, T., Constien, R., de Fougerolles, A., Dorkin, J. R., Narayanannair Jayaprakash, K., 
Jayaraman, M., John, M., Koteliansky, V., Manoharan, M., Nechev, L., Qin, J., Racie, T., Raitcheva, D., Rajeev, K. G., Sah, D. 
W., Soutschek, J., Toudjarska, I., Vornlocher, H. P., Zimmermann, T. S., Langer, R., Anderson, D. G. A combinatorial library of 
lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26, 561-569 (2008). 
 
Allinquant, B., Hantraye, P., Mailleux, P, Moya, K., Bouillot, C., Prochiantz, A. Down-regulation of amyloid precursor protein 
inhibits neurite outgrowth in vitro. J Cell Biol 128, 919-927 (1995). 
 
Alnylam Pharmaceuticals, Inc. Alnylam scientists presents new research on expanded delivery of RNAi therapeutics. 
<http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle2&ID=1480571&highlight=> (2010). 
 
Ambros, V. microRNAs: tiny regulators with great potential. Cell 107, 823-826 (2001). 
 
Araki, N., Johnson, M. T., Swanson, J. A. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and 
phagocytosis by macrophages. J Cell Biol 135, 1249-1260 (1996). 
 
Belting, M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 28, 145-151 (2003). 
 
Behlke, M. A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305-320 (2008).  
 
Behr, J.P., Demeneix, B., Loeffler, J.P., Perez-Mutul, J. Efficient gene transfer into mammalian primary endocrine cells with 
lipopolyamine coated DNA. Proc Natl Acad Sci U S A 86, 6982–6986 (1989).  
 
Bendifallah, N. Rasmussen, F. W., Zachar, V., Ebbesen, P., Nielsen, P. E., Koppelhus, U. Evaluation of cell-penetrating 
peptides (CPPs) as vehi-cles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem 17, 750-758 
(2006). 
 
Bernstein, E., Caudy, A. A., Hammond, S. M., Hannon, G. J. Role for a bidentate ribonu-clease in the initiation step of RNA 
interference. Nature 409, 363-366 (2001). 
 
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., Behr, J. P. A versatile vector for gene 
and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92, 7297-7301 
(1995). 
 
Buratti, E., Muro, A. F., Giombi, M., Gherbassi, D., Iaconcig, A., Baralle, F. E. RNA folding affects the recruitment of SR 
proteins by mouse and human polypurinic enhancer elements in the fibronectin EDA exon. Mol Cell Biol 24, 1387-1400 
(2004). 
 
Calin, G. A., Croce, C. M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66, 7390-7394 (2006). 
 
Campbell, J.M., Bacon, T.A., Wickstrom, E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture 
media, sera and cerebrospinal fluid. J Biochem Biophys Methods 20, 259-267 (1990). 
 
Chang, C. W., Choi, D., Kim, W. J., Yockman, J. W., Christensen, L. V., Kim, Y. H., Kim, S. W. Non-ionic amphiphilic 
biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle. J Control Release 118, 
245-253 (2006). 
 
Cheng, Y., Gao, W., Han, F. Phosphorothioate oligonucleotides as potential antiviral compounds against human 
 46 
immunodeficiency virus and herpes viruses. Nucleosides and Nucleotides 10, 155-166 (1991). 
 
Choosakoonkriang, S., Lobo, B.A., Koe, G.S., Joe, J.G., Middaugh, C.R. Biophysical characterization of PEI/DNA complexes. 
J Pharm Sci 92, 1710–1722 (2003). 
 
Christiaens, B., Grooten, J., Reusens, M., Joliot, A., Goethals, M., Vandekerckhove, J., Prochiantz, A., Rosseneu, M. 
Membrane interaction and cellular internalization of penetratin peptides. Eur J Biochem 271, 1187-1197 (2004). 
 
Collins, A., Warrington, A., Taylor, K. A., Svitkina, T. Structural organization of the actin cytoskeleton at sites of clathrin-
mediated endocytosis. Curr Biol 21, doi:10.1016/j.cub.2011.05.048 (2011). 
 
Conner, S. D., Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37-44 (2005). 
 
Console, S., Marty, C., Garcia-Echeverria, C., Schwendener, R., Ballmer-Hofer, K. An-tennapedia and HIV transactivator of 
transcription (TAT) "pro-tein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell 
surface glycosaminoglycans. J Biol Chem 278, 35109-35114 (2003). 
 
Crombez, L., Aldrian-Herrada, G., Konate, K., Nguyen, Q. N., McMaster, G. K., Brasseur, R., Heitz, F., Divita, G. A new 
potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 1, 95-103 (2009). 
 
Crooke, S. T., ed. Antisense Drug Technology: Principles, Strategies and Applications. New York: Marcel Dekker (2001). 
 
Czech, B., Hannon, G. J. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 12,  
19-31 (2011). 
 
Davidson, B. L., McCray, P. B. Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 12, 329-340 
(2011). 
 
Davis, M. E., Chen, Z., Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug 
Discov 7, 771-782 (2008). 
 
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., Ribas, A. 
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1071 
(2010). 
 
Derossi, D., Joliot, A. H., Chassaing, G. H., Prochiantz, A. The third helix of the Anten-napdeia homeodomain translocates 
through biological membranes. J Biol Chem 269, 10444-10450 (1994). 
 
Deshayes, S., Decaffmeyer, M., Brasseur, R., Thomas, A. Structural polymorphism of two CPP: an important parameter of 
activity. Biochim Biophys Acta 1778, 1197-1205 (2008).    
 
Dickman, D. K., Lu, Z., Meinertzhagen, I. A., Schwarz, T. L. Altered synaptic development and active zone spacing in 
endocytosis mutants. Curr Biol 16, 591-598 (2006). 
 
Dominski, Z., Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl 
Acad Sci U S A 90, 8673-8677 (1993).  
 
Douglas, A. G. L., Wood, M. J. RNA splicing: disease and therapy. Brief Funct Genomics 10, 151-164 (2011). 
 
Du, L., Pollard, J. M., Gatti, R. A. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense 
morpholino oligonucleotides. Proc Natl Acad Sci U S A 104, 6007-6012 (2007). 
 
Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R., Brock, R. A comprehensive model for the cellular uptake of 
cationic cell-penetrating peptides. Traffic 8, 848-66 (2007). 
 
Dürig, J., Dührsen, U., Klein-Hitpass, L., Worm, J., Hansen, J. B., Ørum, H., Wissenbach, M. The novel antisense Bcl-2 inhibitor 
SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 4, 638-647 
(2011). 
 
Edelstein, M. L., Abedi, M. R., Wixon, J. Gene therapy clinical trials worldwide to 2007 – an update. J Gene Med 9, 833-842 
(2007).   
 
Eguchi, A., Meade, B. R., Chang, Y. C., Fredrickson, C. T., Willert, K., Puri, N., Dowdy, S. F. Efficient siRNA delivery into the 
primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27, 567-571 (2009). 
 
EL Andaloussi, S., Holm, T., Langel, Ü. Cell-penetrating peptides: mechanisms and applications. Curr Pharm Des 11, 3597-
611 (2005). 
 
EL Andaloussi, S., Johansson, H. J., Holm, T., Langel, Ü. A novel cell-penetrating peptide, M918, for efficient delivery of 
   47 
proteins and peptide nucleic acids. Mol Ther 15, 1820-1826 (2007a).  
 
EL Andaloussi, S., Johansson, H. J., Lundberg, P., Langel, Ü. Induction of splice correc-tion by cell-penetrating peptide 
nucleic acids. J Gene Med 8, 1262-1273 (2007b). 
 
EL Andaloussi, S. E., Lehto, T., Mäger, I., Rosenthal-Aizman, K., Oprea, I. I., Simonson, O. E., Sork, H., Ezzat, K., Copolovici, 
D. M., Kurrikoff, K., Viola, J. R., Zaghloul, E. M., Sillard, R., Johansson, H. J., Said Hassane, F., Guterstam, P., Suhorutšenko, J., 
Moreno, P. M., Oskolkov, N., Hälldin, J., Tedebark, U., Metspalu, A., Lebleu, B., Lehtiö, J., Smith, C. I., Langel, U. Design of a 
peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 39, 
3972-3987 (2010). 
 
Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., Tuschl, T. Functional anatomy of siRNAs for mediating 
efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J, 20, 6877-6888 (2001a).  
 
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA 
interference in cultured mammalian cells. Nature 411, 494-498 (2001b). 
 
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., 
Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., Kauppinen, S. LNA-mediated microRNA silencing in non-human 
primates. Nature 452, 896-899 (2008).  
 
Elmquist, A., Lindgren, M., Bartfai, T., Langel, Ü. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier 
functions. Exp Cell Res 269, 237-244 (1998). 
 
Fabian, M. R., Sonenberg, N., Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu Rev 
Biochem 79, 351-379 (2010). 
 
Faustino, N. A., Cooper, T. A. Pre-mRNA splicing and human disease. Genes Dev 17, 419-437 (2003). 
 
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., Danielsen, M. 
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84, 7413-7417 (1987). 
 
Filion, M. C., Philips, N. C. Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm 162, 159–170 
(1998). 
 
Fire, A., Xu, S., Montgomery, M. K., Kostas, S.A., Driver, S. E., Mello, C. C. Potent and specific genetic interference by 
double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).   
 
Fittipaldi, A., Ferrari, A., Zoppe, M., Arcangeli, C., Pellegrini, V., Beltram, F., Giacca, M. Cell membrane lipid rafts mediate 
caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278, 34141-34149 (2003). 
 
Foerg, C., Merkle, H. P. On the biomedical promise of cell-penetrating peptides: limits versus prospects. J Pharm Sci 97, 144-
162 (2008). 
 
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, 
R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K. N., Maier, M., Nechev, L., Rajeev, K. G., 
Read, T., Röhl, I., Soutschek, J., Tan, P., Wong, J., Wang, G., Zimmermann, T., de Fougerolles, A., Vornlocher, H. P., Langer, R., 
Anderson, D. G., Manoharan, M., Koteliansky, V., Horton, J. D., Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely 
lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 105, 11915-11920 
(2008).   
 
Franklin, R. E., Gosling, R. G. Molecular Configuration in Sodium Thymonucleate. Nature 171, 740-741 (1953). 
 
Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., Suguira, Y. Arginine-rich peptides. An abundant source 
of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276, 5836-5840 
(2001). 
 
Gao, X., Kim, K. S., Liu, D. Nonviral gene delivery: what we know and what is next. AAPS J 9, 92-104 (2007). 
 
Gebhart, C.L., Kabanov, A.V. Evaluation of polyplexes as gene transfer agents. J Control Release 73, 401–416 (2001). 
 
Georges, M. Coppieters, W., Charlier, C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation 
and disease. Curr Opin Genet Dev 17, 166-176 (2007). 
 
Girard, M., Allaire, P. D., McPherson, P. S., Blondeau, F. Non-stoichiometric relationship between clathrin heavy and light 
chains revealed by quantitative comparative proteomics of clathrin-coated vesicles from brain and liver. Mol Cell Proteomics 
4, 1145-1154 (2005). 
 
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., 
 48 
Platenburg, G. J., Sipkens, J. A., Sitsen, J. M., Aartsma-Rus, A., van Ommen, G. J., Buyse, G., Darin, N., Verschuuren, J. J., 
Campion, G. V., de Kimpe, S. J., van Deutekom, J.C. Systemic administration of PRO051 in Duchenne‟s muscular dystrophy. N 
Engl J Med 16, 1513-1522 (2011). 
 
Graveley, B. R. Sorting out the complexity of SR protein functions. RNA 6, 1197-1211 (2000). 
 
Green, M., Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat 
trans-activator protein. Cell 55, 1179-1188 (1988).  
 
Gump, J. M., June, R. K., Dowdy, S. F. Revised role of glycosaminoglycans in TAT protein transduction domain-mediated 
cellular transduction. J Biol Chem 285, 1500-1507 (2010). 
 
Hammond, S. M., Bernstein, E., Beach, D. & Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene 
silencing in Drosophila cells. Nature 404, 293-6 (2000). 
 
Hershey, A., Chase, M. Independent functions of viral protein and nucleic acid in growth of bacteriophage. J Gen Physiol 36, 
39-56 (1952). 
 
Hewlett, L. J., Prescott, A. R., Watts, C. The coated pit and macropinocytic pathways serve distinct endosome populations. J 
Cell Biol 124, 689-703 (1994). 
 
Hillaireau, H., Couvreur, P. Nanocarriers‟ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66, 2873-2896 (2011). 
 
Howes, M. T., Mayor, S., Parton, R. G. Molecules, mechanisms, and cellular roles of clathrin-independent endocytosis. Curr 
Opin Cell Biol 22, 519-527 (2010). 
 
Howl, J., Nicholl, I. D., Jones, S. The many futures of cell penetrating peptides: how soon is now? Biochem Soc Trans 35, 767-
769 (2007). 
 
Hwa Kim, S., Hoon Jeong, J., Chul Cho, K., Wan Kim, S., Gwan Park, T. Target-specific gene silencing by siRNA plasmid 
DNA complexed with folate-modified polyethylenimine. J Control Release 104, 223-232 (2006).   
 
Hällbrink, M., Florén, A., Elmquist, A., Pooga, M., Bartfai, T., Langel, Ü. Cargo delivery kinetics of cell-penetrating peptides. 
Biochim Biophys Acta 1515, 101-109 (2001). 
 
International Human Genome Sequencing Consortium (IHGSC). Initial sequencing and analysis of the human genome. Nature 
409, 860-921 (2001). 
 
Ivanova, G. D., Arzumanov, A., Abes, R., Yin, H., Wood, M. J. A., Lebleu, B., Gait, M. J. Improved cell-penetrating peptide-
PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 20, 6418-
6428 (2008). 
 
Jeyaseelan, K. Herath, W. B., Armugam, A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets 
11, 1119-1129 (2007). 
 
Joliot, A. H., Triller, A., Volovitch, M., Pernelle, C., Prochiantz, A. Alpha-2,8-polysialic acid is the neuronal surface receptor 
of antennapedia homeobox peptide. New Biol 3, 1121-1134 (1991). 
 
Jung, N., Haucke, V. Clathrin-mediated endocytosis at synapses. Traffic 8, 1129-1136 (2007). 
 
Kang, S. H., Cho, M. J., Kole, R. Up-regulation of luciferase gene expression with anti-sense oligonucleotides: implications 
and applications in functional assay development. Biochemistry 37, 6235-6239 (1998). 
 
Ke, W., Shao, K., Huang, R., Han, L., Liu, Y., Li. J., Kuang, Y., Ye, L., Lou, J., Jiang, C. Gene delivery targeted to the brain 
using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30, 6976-6985 (2009). 
 
Kim, D-H., Behlke, M. A., Rose, S. D., Chang, M-S.Choi, S., Rossi, J. J. Synthetic dsRNA Dicer substrates enhance RNAi 
potency and efficacy. Nat Biotechnol 23, 222-226 (2005). 
 
Kim, J., Kim, S. W., Kim, W. J. PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial 
growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. Oligonucleotides 21, 101-107 (2011). 
 
Kinali, M, Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, 
P., Garralda, M. E., Rutherford, M., McCulley, C., Popplewell, L., Graham, I. R., Dickson, G., Wood, M. J., Wells, D. J., Wilton, 
S. D., Kole, R., Straub, V., Bushby, K., Sewry, C., Morgan, J. E., Muntoni, F. Local restoration of dystrophin expression with the 
morpholino oligomer AVI-4658 in Ducenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-
concept study. Lancet Neurol 8, 918-928 (2009).  
 
Kircheis, R., Kichler, A., Wallner, G., Kursa, M., Ogris, M., Felzmann, T., Buchberger, M., Wagner, E. Coupling of cell-binding 
   49 
ligands to polyethylenimine for targeted gene delivery. Gen Ther 4, 409-418 (1997). 
 
Konate, K., Crombez, L., Deshayes, S., Decaffmeyer, M., Thomas, A., Brasseur, R., Aldrian, G., Heitz, F., Divita, G. Insight into 
the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry 49, 3393-
3402 (2010). 
 
Kosuge, M., Takeuchi, T., Nakase, I., Jones, A. T., Futaki, S. Cellular internalization and distribution of arginine-rich peptides as a 
function of extracellular peptide concentration, serum, plasma membrane associated proteoglycans. Bioconjug Chem., 19, 656-664 
(2008). 
 
Kunath, K., von Harpe, A., Fischer, D., Petersen, H., Bickel, U., Viogt, K., Kissel, T. Low-molecular-weight polyethylenimine 
as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo 
distribution with high-molecular-weight polyethylenimine. J Control Release 89, 113-125 (2003). 
 
Laemmli, U. K. Characterization of DNA condensates induced by polyethylene(oxide) and polylysine. Proc Natl Acad Sci U S 
A 72, 4288-4292 (1975). 
 
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, 
W. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).  
 
Lee, D., Mohapatra, S. S. Chitosan nanoparticle-mediated gene transfer. Methods Mol Biol 433, 127-140 (2008). 
 
Letoha, T., Gaal, S., Somlai, C., Venkei, Z., Glavinas, H., Kusz, E., Duda, E., Czaljik, A., Petak, F., Penke, B. Investigation of 
penetratin peptides. Part 2. In vitro uptake of penetratin and two of its derivatives. J Pept Sci 11, 805-811 (2005). 
 
Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. 
Biochim Biophys Acta 1489, 69-84 (1999).  
 
Lingor, P., Koeberle, P., Kügler, S., Bähr, M. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced 
retinal ganglion cell death in vivo. Brain 128, 550-558 (2001). 
 
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., 
Frank-Kamenetsky, M., Yip, K. N., Alvarez, R., Sah, D. W., de Fougerolles, A., Fitzgerald, K., Koteliansky, V., Akinc, A., 
Langer, R., Anderson, D. G. Lipid-like material for low dose, in vivo gene silencing. Proc Natl Acad Sci U S A 107, 1864-1869 
(2010). 
 
Lundberg, M., Johansson, M. Is VP22 nuclear homing an artifact? Nat Biotechnol 19, 713-714 (2001). 
 
Lundberg, P., EL Andaloussi, S., Sütlü, T., Johansson, H., Langel, Ü. Delivery of short interfering RNA using endosomolytic 
cell-penetrating peptides. FASEB J 21, 2664-2671 (2007). 
 
Lundin, K. E., Simonson, O. E., Moreno, P. M. D., Zaghloul, E. M., Oprea, I. I., Svahn, M. G., Smith, C. I. E. Nanotechnology 
approaches for gene transfer. Genetica 137, 47-56 (2009). 
 
Madsen, E. C., Morcos, P. A., Mendelsohn, B. A., Gitlin, J. D. In vivo correction of a Menkes disease model using antisense 
oligonucleotides. Proc Natl Acad Sci U S A 105, 3909-3914 (2008). 
 
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K. Tumor vascular permeability and the EPR effect in macromolecular 
therapeutics: a review.  J Control Release 65, 271-284 (2000). 
 
Maksymowych, W., Blackburn, W., Tami, J.A., Shanahan, W. R. A pilot study of ISIS 2302, an antisense 
oligodeoxynucleotide, in patients with active rheumatoid arthritis. J Rheumatol 29, 447-53 (2002). 
 
Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of 
tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46, 6387-6392 (1986).  
 
Mayor, S. Pagano, R. E. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8, 603-612 (2007). 
 
McClorey, G., Moulton, H.M., Iversen, P.L., Fletcher, S., Wilton, S.D. Antisense oli-gonucleotide-induced exon skipping 
restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13, 1373-81 (2006). 
 
Merdan, T., Kunath, K., Petersen, H., Bakowsky, U., Voigt, K. H., Kopecek, J., Kissel, T. PEGylation of poly(ethylene imine) 
affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous 
injection into mice. Bioconjug Chem 16, 785-792 (2005). 
 
Merrifield, R.B. Solid Phase Peptide Synthesis. 1. The synthesis of a tetrapeptide. J Am Chem Soc 85, 2149-2154 (1963). 
 
Miescher, F. Ueber die chemische Zusammensetzung der Eiterzellen. Med-Chem 4, 441-460 (1871). 
 
 50 
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., Freier, S. 
M. Evaluation of 2'-modified oligonucleotides con-taining 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol 
Chem 268, 14514-22 (1993). 
 
Morris, M.C., Vidal, P., Chaloin, L., Heitz, F., Divita, G. A new peptide vector for efficient delivery of oligonucleotides into 
mammalian cells. Nucleic Acids Res 25, 2730-6 (1997). 
 
Morrisey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., 
Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C.S., Jeffs, L.B., Judge, A., Maclachlan, I., and Polisky, 
B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23, 1002–1007 (2005). 
 
Moulton, H.M., Hase, M.C., Smith, K.M., Iversen, P.L. HIV Tat peptide enhances cellular delivery of antisense morpholino 
oligomers. Antisense Nucleic Acid Drug Dev 13, 31-43 (2003). 
 
Nakase, I., Niwa, M., Takeuchi, T., Sonomura, K., Kawabata, N., Koike, Y., Takehashi, M., Tanaka, S. Ueda, K., Simpson, J. 
C., Jones, A. T., Sugiura, Y. Futaki, S. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin 
rearrangement. Mol Ther 10, 1011-1022 (2004). 
 
Nakase, I., Tadokoro, A., Kawabata, N., Takeuchi, T., Katoh, H., Hiramoto, K., Negishi, M., Nomizu, M., Sugiura, Y., Futaki, 
S. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization 
and macropinocytosis. Biochemistry 46, 492-501 (2007). 
 
Nie, C., Liu, C., Chen, G., Dai, J., Li, H., Shuai, X. Hepatocyte-targeted psiRNA delivery mediated by galactosylated 
poly(ethylene glycol)-graft-polyethylenimine in vitro. J Biomater Appl May 28 [Epub ahead of print] (2010). 
 
Nielsen, P. E., Egholm, M., Berg, R. H., Buchardt, O. Sequence-selective recognition of DNA by strand displacement with a 
thymine-substituted polyamide. Science 254, 1497-1500 (1991). 
 
Nirenberg, M. W., Matthaei, J. H. The dependence of cell-free protein synthesis in E. coli upon naturally occurring or synthetic 
polyribonucleotide. Proc Natl Acad Sci U S A 47, 1588-1602 (1961). 
 
Ochs, H. D., Smith, C. I. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 75, 287-299 
(1996). 
 
Oehlke, J., Scheller, A., Wiesner, B., Krause, E., Beyermann, M., Klauschenz, E., Melzig, M., Bienert, M. Cellular uptake of 
an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-
endocytically. Biochim Biophys Acta 1414, 127-139 (1998).  
 
Orr, R. M. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 3, 288-294 (2001). 
 
Osada, H., Takahashi, T. MicroRNAs in biological process and carcinogenesis. Carcinogenesis 28, 2-12 (2007). 
 
Padari, K., Säälik, P., Hansen, M., Koppel, K., Raid, R., Langel, Ü. Cell transduction pathways of transportans. Bioconjug 
Chem 16, 1399-1410 (2005). 
 
Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., Montuenga, L. M. Alternative splicing: an emerging topic in 
molecular and clinical oncology. Lancet Oncol 8, 349-357 (2007). 
 
Parton, R. G., Richards, A. A. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. 
Traffic 4, 724-738 (2003). 
 
Parton, R. G., Simmons, K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 8, 185-194 (2007).  
 
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., 
Kaye, E. M., Shihabuddin, L. S., Krainer, A. R., Bennett, C. F. Antisense oligonucleotides delivered to the mouse CNS 
ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3, 72ra18 (2011).     
 
Pearse, B. M. Clathrin: a unique protein associated with intracellular transfer of membrane by coated vesicles. Proc Natl Acad 
Sci U S A 73, 1255-1259 (1976). 
 
Pelkmans, L., Helenius, A. Endocytosis via caveolae. Traffic 3, 311-320 (2002). 
 
Pollard, H., Remy, J. S., Loussouarn, G., Demolombe, S., Behr, J. P. Escande, D. Polyethylenimine but not cationic lipids 
promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem 273, 7507–7511 (1998).  
 
Pooga, M., Hällbrink, M., Zorko, M., Langel, Ü. Cell penetration by transportan. FASEB J 12, 67-77 (1998). 
 
Pooga, M., Soomets, U., Hällbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J. X., Xu, X. J., Wiesenfeld-Hallin, Z., 
Hökfeldt, T., Bartfai, T., Langel, Ü. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain 
   51 
transmission in vivo. Nat Biotechnol 16, 857-861 (1998). 
 
Poon, G. M. K., Gariépy, J. Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. 
Biochem Soc Trans 35, 788-793 (2007). 
  
Pratt, A. J., MacRae, I. J. The RNA-induced silencing complex: A versatile gene silencing machine. J Biol Chem 284, 17897-
17901 (2009).  
 
Ray, A., Nordén, B. Peptide nucleic acid (PNA): its medical and biotechnological applica-tions and promise for the future. 
FASEB J 14, 1041-1060 (2000). 
 
Rayburn, E. R., Zhang, R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible. Drug 
Discov Today 13, 513-521 (2008).   
 
Richard, J. P., Melikov, K., Brooks, H., Prevot, P., Lebleu, B., Chernomordik, L. V. Cellular uptake of unconjugated TAT 
peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280, 15300-15306 (2005). 
 
Richard, J. P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M. J., Chernomordik, L. V., Lebleu, B. Cell-penetrating 
peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278, 585-590 (2003). 
 
Robbins, M., Judge, A., Maclachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89-101 (2009).  
 
Rothbard, J. B., Garlington, S., Lin, Q., Kirschberg, T., Kreider, E., McGrane, P. L., Wender, P.A., Khavari.,P. A. Conjugation 
of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6, 1253- 1257 
(2000). 
 
Sabharanjak, S., Sharma, P., Parton, R. G., Mayor, S. GPI-anchored proteins are delivered to recycling endosomes via a 
distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell 2, 411-423 (2002). 
 
Said Hassane, F., Saleh, A. F., Abes, R. Gait, M. J., Lebleu, B. Cell penetrating peptides: overview and applications to the 
delivery of oligonucleotides. Cell Mol Life Sci 67, 715-26 (2010). 
 
Sano, M., Sierant, M., Miyagishi, M., Nakanishi, Takagi, Y., Sutou, S. Effect of asymmet-ric terminal structures of short RNA 
duplexes on the RNA interference activity and strand selection. Nucleic Acids Res 18, 5812-5821 (2008). 
 
Scaffidi, P., Misteli, T. Reversal of the cellular phenotype in the premature ageing disease Hutchinson-Gilford Progeria 
Syndrom. Nat Med 11, 440-445 (2005). 
 
Scherer, L. J., Rossi, J. J. Approaches for the sequence specific knockdown of mRNA. Nat Biotechnol 21, 1457-1465 (2003).  
 
Schlee, M., Hornung, V., Hartmann, G. siRNA and isRNA: two edges of one sword. Mol Ther 14, 463-470 (2006). 
 
Schwarz, D. S., Ding, H., Kennington, L, Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z., Zamore, P. 
D. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2, e140 (2006). 
 
Semple, S.C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W., Stebbing, D., Crosley, E. J., Yaworski, E., 
Hafez, I. M., Dorkin, J. R., Qin, J., Lam, K., Rajeev, K. G., Wong, K. F., Jeffs, L. B., Nechev, L., Eisenhardt, M. L., Jayaraman, 
M., Kazem, M., Maier, M. A., Srinivasulu, M., Weinstein, M. J., Chen, Q., Alvarez, R., Barros, S. A., De, S., Klimuk, S. K., 
Borland, T., Kosovrasti, V., Cantley, W. L., Tam, Y. K., Manoharan, M., Ciufolini, M. A., Tracy, M. A., de Fougerolles, A., 
MacLachlan, I., Cullis, P. R., Madden, T. D., Hope, M. J. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 
28, 172-176 (2010). 
 
Sharp, P. A. Split genes and RNA splicing. Cell 77, 805-815 (1994). 
 
Sheng, M., Kim, M. J. Postsynaptic signaling and plasticity mechanisms. Science 298, 776-780 (2002). 
 
Shiraishi, T., Nielsen, P.E. Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates. FEBS Lett 
580, 1451-6 (2006). 
 
Simeoni, F., Morris, M.C., Heitz, F., Divita, G. Insight into the mechanism of the peptide-based gene delivery system MPG: 
implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31, 2717-2724 (2003). 
 
Slater, T. F., Sawyer, B., Straeuli, U. Studies on succinate-tetrazolium reductase systems. Iii. Points of coupling of four 
different tetrazolium salts. Biochim Biophys Acta 77, 383-393 (1963). 
 
Somia, N., Verma, I. M. Gene therapy: trials and tribulations. Nat Rev Genet 1, 91-99 (2000). 
 
Soomets, U., Lindgren, M., Gallet, X., Hällbrink, M., Elmquist, A., Balaspiri, L., Zorko, M., Pooga, M., Brasseur, R., Langel, 
Ü. Deletion analogues of transportan. Biochim Biophys Acta 1467, 165-176 (2001). 
 52 
 
Spitzer, S., Eckstein, F. Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic 
Acids Res 16, 11691-704 (1988). 
 
Srebrow, A., Kornblihtt, A. R. The connection between splicing and cancer. J Cell Sci 119, 2635-2641 (2006). 
 
Stephenson, M. L., Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. 
Proc Natl Acad Sci U S A 75, 285-288 (1978). 
 
Sung, S. J., Min, S. H., Cho, K. Y., Lee, S., Min, Y. J., Yeom, Y. I., Park, J. K. Effect of polyethylene glycol on gene delivery 
of polyethyleneimine. Biol Pharm Bull 26, 492-500 (2003). 
 
Swanson, J.A. Shaping cups into phagosomes and macropinosomes. Nat Rev Mol Cell Biol 9, 639-649 (2008). 
 
Takei, K., McPherson, P. S., Schmid, S. L. and De Camilli, P. Tubular membrane invaginations coated by dynamin rings are 
induced by GTP-gamma S in nerve terminals. Nature 374, 186-190 (1995) 
 
Takei, K., Haucke, V. Clathrin-mediated endocytosis: membrane factors pull the trigger. Trends Cell Biol 11, 385-391 (2001).  
 
Thorén, P. E. G., Persson, D., Isaksson, P., Goksör, M., Önfeldt, A., Nordén, B. Uptake of analogs of penetratin, Tat(48-60) 
and oligoarginine in live cells. Biochem Biophys Res Commun 18, 100-107 (2003).  
 
Tros de Ilarduya, C., Sun, Y., Düzgünes, N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 40, 159-170 (2010). 
 
Tong, A. W., Jay, C. M., Senzer, N., Maples, P. B., Nemunaitis, J. Systemic therapeutic gene delivery for cancer: crafting 
Paris‟ arrow. Curr Gene Ther 9, 45-60 (2009). 
  
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., Maraganore, J. A status 
report on RNAi therapeutics. Silence 1, 14 (2010).  
 
van den Berg, A., Mols, J., Han, J. RISC-target interaction: Cleavage and translational suppression. Biochim Biophys Acta 11, 
668-677 (2008). 
 
Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001). 
 
Viola, J. R., EL Andaloussi, S., Oprea, I. I., Smith, C. I. Non-viral nanovectors for gene delivery: factors that govern 
successful therapeutics. Expert Opin Drug Deliv 7, 721-35 (2010).  
 
Vivés, E., Brodin, P., Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma 
membrane and accumulates in the cell nucleus. J Biol Chem 272, 16010-16017 (1997). 
 
Wadia, J. S., Stan, R. V., Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after 
lipid raft macropinocytosis. Nat Med 10, 310-315 (2004). 
 
Waehler, R., Russell, S. J., Curiel, D. T. Engineered targeted viral vectors for gene therapy. Nat Rev Genet 8, 573-587 (2007). 
 
Wang, J., Lu, Z., Wientjes, M. G., Au, J. L. Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12, 492-503 (2010). 
 
Waters, J., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., Cotter, F. E. Phase I clinical and 
pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18, 
1812-1823 (2000). 
 
Watson, J. D., Crick, F. H. C.  A Structure for Deoxyribose Nucleic Acid. Nature 171, 737-738 (1953). 
 
Watts, J. K., Deleavey, G. F., Damha, M. J. Chemically modified siRNA: tools and applications. Drug Discov Today 13, 842-
855 (2008). 
 
Wolff, J. A., Williams, P., Acsadi, G., Jiao, S., Jani, A., Chong, W. Conditions affecting direct gene transfer into rodent muscle 
in vivo. Biotechniques 11, 474-485 (1991).  
 Wolf, Y., Pritz, S., Abes, S., Bienert, M., Lebleu, B., Oehlke, J. Structural requirements for cellular uptake and antisense 
activity of peptide nucleic acids conjugated with various peptides. Biochemistry 45, 14944-14954 (2006). 
 
Wolfert, M. A., Schacht, E. H., Toncheva, V., Ulbrich, K., Nazarova, O., Seymour, L. W.  Characterization of vectors for gene 
therapy formed by self-assembly of DNA with synthetic block co-polymers. Hum Gene Ther 7, 2123-2133 (1996). 
 
Xu, L., Anchordoquy, T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the 
delivery of nucleic acid-based therapeutics. J Pharm Sci 100, 38-52 (2011). 
 
   53 
Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L., Shanahan, W. R. A placebo-
controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114, 1133-1142 
(1998). 
 
Yin, H., Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., Wood, M. J. A. Cell-penetrating peptide-conjugated 
antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 24, 3909-
3918 (2008). 
 
Yin, H., Saleh, A. F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M. J., 
Wood, M. J. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and 
phenotypic correction in mdx mice. Mol Ther 19, 1295-1303 (2011). 
 
Zamecnik, P. C, Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific 
oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75, 280-284 (1978). 
 
Zhang, G., Wooddell, C. I., Hegge, J. O., Griffin, J. B., Huss, T., Braun, S., Wolff, J. A. Functional efficacy of dystrophin 
expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. Hum Gene Ther 21, 221-37 (2010). 
 
Zhou, X. H., Klibanov, A. L., Huang, L. Lipophilic polylysines mediate efficient DNA transfection in mammalian cells. 
Biochim Biophys Acta 1065, 8 -14 (1991). 
 
Zimmermann, T. S, Lee, A. C., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., 
John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Rohl, I., Seiffert, S., Shanmugam, 
S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., 
Vornlocher, H. P., MacLachlan, I. RNAi-mediated gene silencing in non-human primates. Nature 441, 111-4 (2006). 
 
Zorko, M., Langel, Ü. Cell-penetrating peptides: mechanisms and kinetics of cargo delivery. Adv Drug Deliv Rev 57, 529-545 
(2005). 
 
 
 
 
  
 54 
 
